European Neuropsychopharmacology

Clinical Differences in Response to Mianserin and Fluoxetine in Depressive Patients
pp. 125+126-125+126(1)
Authors: Lavergne F.; Berlin I.; Payan C.; Besancon G.

New Observations in the Life Course of Unipolar Major Depression: Risk Factors & Treatment Goals
pp. 1-1(1)
Author: Judd L.L.

Radiotelemetry: A Model for Measuring Precipitated and Spontaneous Lorazepam Withdrawal
pp. 1-1(1)
Authors: Elliot E.; White J.

Alcoholism and Liver Enzymes
pp. 1-1(1)
Authors: Markovic P.; Poleksic L.; Lazarevic K.

The Ambulatory Monitor -- An Objective Method of Alcohol Withdrawal Assessment in Humans
pp. 1-1(1)
Authors: Humeniuk R.E.; White J.M.

Double-Blind Comparative Trial with Carbamazepine vs Diazepam Treatment of Alcohol Withdrawal
pp. 1-2(2)
Authors: Kalyoncu O.A.; Beyazyurek M.; Kuru L.; Solukcu R.; Yazman U.

Pharmacotherapy of Alcoholism: Effects of Clinically Evaluated Compounds in a Rat Model of Alcoholism
pp. 2-2(1)
Authors: De Vry J.; Schreiber R.; Smith J.; de Beun R.

The Influence of Selected Quinolones on Central Action of Ethyl Alcohol in Laboratory Animals
pp. 2-2(1)
Authors: Strzelec J.; Czarnecka E.; Pietrzak B.

Use of Benzodiazepines in Opiate Addicted Patients -- Results of an Inquiry in Basle
pp. 2-2(1)
Authors: Ladewig D.; Simoni H.

Cannabis Withdrawal Syndrome: Laboratory Artifact or Clinically Important?
pp. 2-2(1)
Author: Jones R.T.

Cigarette Smoking and Mood: The Psychological Processes which Underlie Nicotine Addiction
pp. 2-3(2)
Author: Parrott A.C.

Effects of Cigarette Smoking on Cerebral Circulation in Normal Adults
pp. 3-3(1)
Authors: Nagata K.; Shinohara T.; Matsuoka S.; Kanno I.; Domino E.F.

Are Genetic Influences Shared Across Drug Categories?: Evidence from a Twin Study
pp. 3-3(1)
Authors: Tsuang M.T.; Lyons M.J.; Meyer J.; Eisen S.; Goldberg J.; True W.

CYP2D6 Drug Interaction Potential of Four SSRI's Using In Vivo Dextromethorphan
pp. 3-3(1)
Authors: Ereshefsky L.; Riesenman C.L.; Lam Y.W.F.; Simpson J.

Contributions of Cytochrome P450 Isozymes to Metabolic Pathways of Haloperidol
pp. 3-3(1)
Authors: Coutts R.T.; Fang J.; Baker G.B.; Silverstone P.H.

Toxic Haloperidol Metabolites in Human Brain
pp. 4-4(1)
Authors: Eyles D.; Stedman T.; McGrath J.; Pond S.

Plasma Neuroleptic Level and Clinical Effects of Nemonapride-Factors Weakening the Correlation
pp. 4-4(1)
Authors: Fujimaki H.; Yamaguchi N.; Morokawa Y.; Kamimura M.; Kosaka A.; Ohta T.; Watanabe H.; Nagatu Y.; Aoba A.

Plasma Levels of Clozapine and Norclozapine in Chronic Schizophrenics
pp. 4-4(1)
Authors: Mauri M.C.; Giuliani E.; Coppola M.T.; Sicaro A.; Bravin S.; Invernizzi G.

Postmortem Concentrations of Clozapine and Desmethylclozapine in Two Coronial Cases
pp. 4-4(1)
Authors: McIntyre I.M.; Fayle P.; Olumbe A.K.; Drummer O.H.

Inhibition of Clomipramine Metabolism by Fluvoxamine (In Vivo and In Vitro Data)
pp. 4-5(2)
Authors: Haertter S.; Bornemann T.; Hiemke C.; Arand M.; Oesch F.

Plasma Concentrations of Trans-10-Hydroxy Metabolites have Relation with Clinical Effects of Amitriptyline in Depression
pp. 5-5(1)
Authors: Someya T.; Shimoda K.; Yasuda S.; Morita S.; Shibasaki M.; Takahashi S.

Plasma Levels of Sertraline and the Clinical Response
pp. 5-5(1)
Authors: Kumar V.; Garcia V.; Loewenstein D.

Prevalence of Depressive Symptoms in the Elderly, A Community Study
pp. 5-5(1)
Authors: Korner A.; Lauritzen L.

Biological Abnormalities in Depression in the Elderly
pp. 5-6(2)
Authors: Dahabra S.; Moore B.; Ashton H.; Bahrainian M.; Marsh R.; Ferrier I.N.

Outcome of Depression in Elderly Patients Changed from Tricyclic and other Antidepressants to Fluoxetine
pp. 6-6(1)
Authors: McWilliam C.; Hanna M.

Cardiac Tolerability of Trimipramine in the Elderly
pp. 6-6(1)
Authors: Malsch U.; Jager K.; Schwalb B.; Fischer W.

The Depression-Anxiety Syndrome in Dementia
pp. 6-6(1)
Authors: Wallin A.; Karlsson I.

Effects of Electroconvulsive Therapy on Cognitive Function in Geriatric Patients with Depression
pp. 6-6(1)
Authors: Ohta T.; Morokawa Y.; Watanabe H.; Yamaguchi N.; Aoba A.

Sleep and Psychotropic Drug Consumption: Relationships with Aging
pp. 6-7(2)
Authors: Ohayon M.M.; Caulet M.; Lemoine P.

Pharmacological Profile of GV150526A a Novel Glycine Antagonist for Stroke
pp. 7-7(1)
Authors: Ratti E.; Gaviraghi G.; Pietra C.; Trist D.; Reggiani A.

Is Paroxetine in Post-Stroke Depression Useful?
pp. 7-7(1)
Authors: Rutigliano G.; Vadruccio F.

Natural Killer Cell Activity and In Vitro Responsiveness to Glucocorticoids and Cytokines in the Elderly and in Alzheimer's Disease
pp. 7-7(1)
Authors: Ravizza L.; Prolo P.; Griot G.; Masera R.G.; Mantovan M.; Staurenghi A.; Tarenzi L.; Lazzero A.; Angeli A.

Longitudinal Course of Immune Changes in Severe Depression
pp. 7-8(2)
Authors: Hickie I.; Silove D.; Wakefield D.; Lloyd A.; Bennett B.

The Effects of Potentiation with Lithium of Antidepressant Drugs on Immunological Indices in Refractory Depression
pp. 8-8(1)
Authors: Sluzewska A.; Rybakowski J.K.; Sobieska M.; Suwalska A.; Wiktorowicz K.

T-Cells and NK-Cells in Schizophrenia: Comparison before and during Neuroleptic Therapy
pp. 8-8(1)
Authors: Muller N.; Primbs J.; Hadjamu M.; Putz A.; Gruber R.

Are Immunological Alterations in Schizophrenia Due to Psychopharmacological Treatment?
pp. 8-8(1)
Authors: Sperner-Unterweger B.; Miller C.; Witworth A.; Kemmler J.; Gassner M.; Eisterer W.; Taler J.

Effect of Cadmium on Immune Function and Lymphocyte Calcium Homeostasis
pp. 8-8(1)
Authors: Bin X.; Zhan L.; Zhiming L.; Xian Z.

In Vitro and In Vivo Effects of Anxiety and Benzodiazepines on Immune Parameters and Lymphocyte Benzodiazepine Receptor mRNA
pp. 8-9(2)
Authors: Rocca P.; Beoni A.M.; Ravizza L.; Ferrero P.; Eva C.

Bipolar Mixed Illness
pp. 9-9(1)
Authors: Marneros A.; Rohde A.; Deister A.

Mania Secondary to HIV Infection
pp. 9-9(1)
Authors: Ellen S.; Mijch A.; Cockram A.; Crowe S.; Judd F.

Pharmacological Treatment of Mania (The Use of Code-HD)
pp. 9-9(1)
Author: Gaszner P.

Renal Function after 20 Years of Lithium Therapy
pp. 9-9(1)
Authors: Walker R.; Burrows G.; Schweitzer I.; Grounds D.; Davies B.

Superiority of Lithium over Verapamil in Mania: A Randomized Controlled Trial
pp. 9-10(2)
Authors: Walton S.A.; Berk M.; Brook S.

Baseline Hypermetabolism May Predict Carbamazepine Response, and Hypometabolism Nimodipine Response in Mood Disorders
pp. 10-10(1)
Authors: Ketter T.A.; Kimbrell T.A.; George M.S.; Stein R.M.; Willis M.W.; Benson B.E.; Frye M.A.; Cora-Locatelli G.; Post R.M.

GH & PRL Response to Apomorphine in Bipolar and Unipolar Depression
pp. 10-10(1)
Authors: Walsh A.; McPherson H.; Silverstone T.

D-Fenfluramine-Induced Prolactin Release in Bipolar Mania
pp. 10-10(1)
Authors: Thakore J.H.; O'Keane V.; Dinan T.G.

Factors Affecting Melatonin Sensitivity to Light: Relevance for a Putative Marker of Bipolar Affective Disorder
pp. 10-10(1)
Authors: Nathan P.J.; Norman T.R.; Burrows G.D.

Lithium Therapy: Some Considerations About Safety
pp. 10-11(2)
Authors: Rutigliano G.; Vadruccio F.

The Treatment of Adolescent Depression: Where is the Evidence?
pp. 11-11(1)
Author: Martin G.

Peculiarities of Depressive States in Children
pp. 11-11(1)
Authors: Chebykina T.; Curlynd Z.; Chustrak A.; Chebykin A.; Gavrichko V.

The Use of Electroconvulsive Therapy in Young People
pp. 11-11(1)
Authors: Walter G.; Rey J.

Sertraline Treatment in Children and Adolescents: Tolerability, Efficacy and Pharmacokinetics
pp. 11-11(1)
Authors: Johnston H.; Rosenthal M.; Ferguson J.; Sallee F.; Blumer J.; Alderman J.; Wolkow R.

Risperidone Added to Methylphenidate in Attention Deficit Hyperactivity Disorder
pp. 11-12(2)
Author: Cosgrove P.V.F.

Impact of Stress-Factors of Technical Accident on Emotional Sphere of Children
pp. 12-12(1)
Authors: Chustrak A.; Chebykin A.

Prophylactic of Emotional Stress in Schoolchildren
pp. 12-12(1)
Author: Chebykin A.

Handedness and Behavior Problems in Children
pp. 12-12(1)
Authors: S. K.M.; Y. J.S.; K. J.O.

Role of Body Build and Temperament in Children Treated because of Neurotic Disorders
pp. 12-12(1)
Authors: Lintsi M.; Liivamiagi J.; Aluoja A.

Eating Disorders and Diagnostic Subtypes: Targeted Use of Antidepressants
pp. 12-12(1)
Authors: Giannelli A.; Lugo F.; Zappulli D.; Codazzi L.; Papa R.; Penati G.; Redaelli G.; Cavagnini F.

The Augmented Platelet Intracellular Calcium Response to Serotonin in Anorexia Nervosa but not Bulimia may be Due to Subsyndromal Depression
pp. 13-13(1)
Authors: Berk M.; Kessa K.; Szabo C.P.; Butkow N.

Pain Sensitivity, Alexithymia, and Depression in Patients with Eating Disorders
pp. 13-13(1)
Authors: de Zwaan M.; Biener D.; Bach M.; Wiesnagrotzki S.; Stacher G.

Olfactory Sensitivity in Eating Disorders
pp. 13-13(1)
Authors: Sirota P.; Shamir D.; Mitrany E.

On the Possible Role of Testosterone in Serotonin-Related Psychiatric Disorders in Women
pp. 13-13(1)
Authors: Eriksson E.; Andersch B.; Bergman L.; Bing O.; Kakaoulidis P.; Sundblad C.; Wikander I.

Antidepressants and Breastfeeding
pp. 13-13(1)
Authors: Buist A.; Norman T.

Postpartum Psychoses: Long-Term Course and Outcome
pp. 13-14(2)
Authors: Rohde A.; Marneros A.

A Review of the Nosological Status and Aetiological Theories of Postpartum Psychosis
pp. 14-14(1)
Authors: George T.; Hackwood J.

Comparison of Undergraduate and Postgraduate Psychiatric Training in Eastern Europe
pp. 14-14(1)
Authors: Hoschl C.; Sartorius N.; Mohr P.

Therapeutic Effect of Yohimbine in Organic and Non-organic Erectile Dysfunction
pp. 14-14(1)
Authors: Mann K.; Klingler T.; Roschke J.; Benkert O.; Witzsch U.

Does Plasma Free-MHPG Increase in the Delirious State?
pp. 14-14(1)
Authors: Nakamura J.; Uchimura N.; Yamada S.; Tanaka M.

Antiulcer Properties of Some Prolin-Containing Oligopeptides
pp. 14-15(2)
Authors: Samonina G.E.; Abramova M.A.; Ashmarin I.P.

Betahistine and Neuroplasticity in Vertigo (Metaanalysis)
pp. 15-15(1)
Author: Molnar G.

Treatment of Anxiety Disorders in Rheumatic Heart Disease
pp. 15-15(1)
Author: Khokhlov A.

Mental Disorders in Rheumatic Heart Disease
pp. 15-15(1)
Authors: Grigoryeva E.; Khokhlov A.

Peer Review System Accepted for Three Year Hospital Accreditation
pp. 15-15(1)
Author: Freed E.

Epilepsy in Forensic Psychiatry
pp. 15-15(1)
Authors: Joubert A.F.; vRensburg P.H.J.J.; Gagiano C.A.; Verschoor T.

Further Studies with Marine Compound NIO-50
pp. 15-16(2)
Author: Puri V.N.

Negative Priming in High Schizotypes, Psychosis and after Ketamine
pp. 16-16(1)
Authors: Healy D.; Watson F.; Harborne G.; Tipper S.

The Need for Faster and More Effective Antidepressants
pp. 16-16(1)
Author: Deakin J.F.W.

Augmentation of Antidepressant Effects with 5HT-_1A Antagonists. Basic and Clinical Studies
pp. 16-16(1)
Authors: Artigas F.; Romero L.; Perez V.; Alvarez E.

The 5-HT1A Receptor Antagonist WAY-100635 enhances the Behavioural Effects of SSRIs
pp. 16-17(2)
Authors: Dourish C.T.; McNicoll C.; Fletcher A.

Present and Future Tools to Improve the Antidepressant Response based on the Differential Properties of 5-HT Receptor Subtypes
pp. 17-17(1)
Authors: Blier P.; Bergeron R.; de Montigny C.

Double-Blind Study on the Effect of Pindolol Addition to Accelerate the Antidepressant Response
pp. 17-17(1)
Author: Chamey D.

Stabilizing Action of Partial Dopamine Receptor Agonists in Psychosis
pp. 17-17(1)
Author: Carlsson A.

The Development of (-)-3PPP as an Antipsychotic Drug
pp. 17-17(1)
Authors: Tamminga C.A.; Lahti A.C.

Neuroimaging to Evaluate Atypical Antipsychotic Compounds: An FDG Pet Study of SDZ MAR 327
pp. 17-18(2)
Authors: Potkin S.; J. W.; Anand R.; Bera R.; Carreon D.; Hartman R.; Keator D.

Preclinical Pharmacology of Dopamine Partial Agonists
pp. 18-18(1)
Authors: Meltzer L.; Davis M.; MacKenzie R.; Pugsley T.; Wise L.; Heffner T.

Late Phase II Study of OPC-14597, a Dopamine Autoreceptor Agonist in Schizophrenic Patients
pp. 18-18(1)
Authors: Toru M.; Miura S.

Somatization across Different Psychopathological States
pp. 18-18(1)
Author: Janca A.

Comorbidity between Somatoform Disorders and Depression
pp. 18-18(1)
Authors: Altamura A.C.; Carta M.G.

Assessment of Somatic Symptoms in Depression and Somatoform Disorders
pp. 19-19(1)
Authors: Kasper S.; Neumeister A.; Praschak-Rieder N.; Heiden A.

Depression and Somatization: A Neurochemical Link?
pp. 19-19(1)
Author: Potter W.

Psychoimmunological and Neuroendocrine Findings in Depression and Somatization
pp. 19-19(1)
Author: Maes M.

Multiple Amyloidogenic Pathways in Alzheimer's Disease -- Which is the Therapeutic Target?
pp. 19-20(2)
Authors: Masters C.L.; Beyreuther K.

Abnormal Homeostasis of pH and Zinc: The Prelude for Cerebral A Amyloid Formation?
pp. 20-20(1)
Authors: Bush A.I.; Atwood C.S.; X. H.; Moir R.D.; Glabe C.G.

Pharamaceutical Research and Development Activities in Alzheimer's Disease
pp. 20-20(1)
Author: Unterbeck A.

NPY Increases in Rat Brain Following Electro-Convulsive Seizures: An Animal Model for the Working Action of ECT
pp. 20-20(1)
Authors: Bolwig T.G.; Mikkelsen J.D.

Genes and the Mechanism of Action of ECT: Focus on 5-HT1A Receptors
pp. 20-20(1)
Authors: Segman R.; Shoham S.; Ebstein R.; Lerer B.

Peripheral and Endocrine Measures of ECT'S Effects: Relation to Side Effects and Outcome
pp. 20-21(2)
Authors: Nutt D.; Smith J.; Williams K.; Wilson S.

Medication Resistance, ECT Response and Relapse Prevention
pp. 21-21(1)
Authors: Sackeim H.A.; Prudic J.; Haskett R.F.; Mulsant B.; Pettinati H.

ECT: Relationships among Therapeutic Outcome, Amnesia, and EEG Response
pp. 21-21(1)
Authors: Weiner R.D.; Krystal A.D.; Coffey C.E.

Preclinical Models of Aggressive Behavior: The Role of Serotonin
pp. 21-21(1)
Author: Eichelman B.

Individual Differences in 5-HT_1A Receptors and Aggressive Behavior in Monkeys
pp. 21-21(1)
Authors: Raleigh M.; Nielsen D.; Goldman D.; Linnoila M.; McGuire M.

Molecular Genetics of Suicidal Behavior
pp. 22-22(1)
Authors: Mann J.J.; Malone K.M.; Nielsen D.L.; Goldman D.; Erdos J.; Gelernter J.

Serotonergic Targets for the Pharmacotherapy of Aggression
pp. 22-22(1)
Author: Nelson D.L.

The Diagnosis, Course, Biological and Neuropathological Correlates of HIV Neurocognitive Disorder
pp. 22-22(1)
Authors: HNRC Group; Grant I.

Pathogenesis of the Aids Dementia Complex in the SIV Model
pp. 22-22(1)
Authors: Berman N.E.J.; Johnson J.K.; Raymond L.; Stephens E.B.; Joag S.; Narayan O.

Animal Models for Neuroaids
pp. 22-22(1)
Authors: Bloom F.E.; Elder J.; Fox H.; Gold L.; Henriksen S.J.; Phillips T.

Current Progress in Developing Rodent Models of HIV/CNS Disease
pp. 23-23(1)
Authors: Vitkovic L.; Basile A.S.; Y. S.

Monocyte Transit Across the Blood-Brain Barrier in AIDS: A Role for Adhesion Molecules and Chemokines
pp. 23-23(1)
Authors: Lyman W.D.; Downie S.A.; Berman J.W.

State-Dependent Regulation of Neuronal Excitability by Dopamine
pp. 23-23(1)
Authors: Surmeier D.J.; Kitai S.T.

Dopamine D2 Receptors in the Ventral Striatum: Multiple Effects or Receptor Subtypes?
pp. 23-23(1)
Author: White F.J.

D2 Receptor Activation in Distinct Striatal Neurons in Comparison with D3 Receptors
pp. 23-24(2)
Authors: Sasa M.; Ishihara K.; Amano T.; Matsubayashi H.; Momiyama T.; Todo N.

D2 Dopamine Receptors in the Short-and Long-Term Modulation of Corticostriatal Transmission
pp. 24-24(1)
Authors: Calabresi P.; Pisani A.; Centonze D.; De Murtas M.; Bernardi G.

Cholinergic and GABAergic Interneurons in the Striatum
pp. 24-24(1)
Authors: Kawaguchi Y.; Aosaki T.; Kubota Y.

Do 'D₂-Like' Dopamine Receptors Mediate Neuronal Excitation or Inhibition: Some Functional-Behavioural Implications
pp. 24-24(1)
Author: Waddington J.L.

Developing New Antipsychotic Drugs and Treatment Strategies: An Overview
pp. 24-24(1)
Author: Copolov D.L.

Immediate Early Gene Expression and the Mechanisms of Action of Atypical Antipsychotics
pp. 25-25(1)
Author: Fibiger H.C.

Pharmacological Genetic Association Studies and Clozapine Response
pp. 25-25(1)
Authors: Kerwin R.; Collier D.; Shaikh S.; Arranz M.

Treatment and Consequences of Relapse in Schizophrenia
pp. 25-25(1)
Author: Lieberman J.A.

Contemporary and Anticipated Approaches to the Reduction of Antipsychotic Induced Side Effects
pp. 25-25(1)
Author: Fleischhacker W.W.

Psychosocial Interventions in Schizophrenia: Partnership into the 21st Century
pp. 25-25(1)
Author: Tarrier N.

Subthreshold Anxiety and Depression Disorders: Prevalence Rates and Needs for Treatment
pp. 25-26(2)
Authors: Maier W.; Lepine J.P.; Franke P.; Weiffenbach O.; Gansicke M.

Efficacy of Pharmacological Treatment in Short Term Anxiety
pp. 26-26(1)
Authors: Boyer P.; Bisserbe J.C.; Patay M.; Lecrubier Y.

Social Phobia: Defining Thresholds for Treatment Intervention
pp. 26-26(1)
Authors: Weiller E.; Bisserbe J.C.; Lecrubier Y.

Psychotropic Drugs Use in Patients with Anxious or Depressive Disorders vs Subthreshold Syndromes
pp. 26-26(1)
Authors: Bisserbe J.C.; Weiller E.; Boyer P.; Lecrubier Y.

Familial Patterns of Comorbidity of Migraine and Mood Disorders
pp. 26-26(1)
Author: Merikangas K.R.

Affective Disorders & Headache Syndromes in the Community
pp. 26-27(2)
Authors: Angst J.; Merikangas K.R.

Pleomorphic Expressions of Bipolarity
pp. 27-27(1)
Author: Akiskal H.S.

Valproate in Migraine Prophylaxis
pp. 27-27(1)
Author: Mathew N.T.

The Bipolar Nature of Migrainous Psychopathology
pp. 27-27(1)
Authors: Himmelhoch J.; Merikangas K.R.

Typical vs. Atypical Antipsychotics in Late-Life Psychosis
pp. 27-27(1)
Authors: Jeste D.V.; Eastham J.H.; Lacro J.P.; Naimark D.; Rockwell E.

Atypical Neuroleptics: Pharmacologic Considerations
pp. 27-28(2)
Authors: Sweet R.A.; Pollock B.G.; Mulsant B.H.; Rosen J.; Henteleff R.

Serotonin-Dopamine Antagonists in Elderly Schizophrenics
pp. 28-28(1)
Authors: Yamawaki S.; Hayashi T.; Yokota N.; Takahashi T.; Sato G.; Tahara Y.

Risperidone for Visual Hallucinations in the Elderly
pp. 28-28(1)
Author: Howard R.J.

Atypical Neuroleptics in Older Monkeys
pp. 28-28(1)
Author: Casey D.E.

Ontogeny of Behavioural Responses to Psychostimulants in Rodents
pp. 28-28(1)
Authors: Alleva E.; Cirulli F.; Laviola G.

The Role of NMDA Systems in the Developmental Neurobehavioral Toxicity of Phencyclidine
pp. 28-29(2)
Author: Scalzo F.M.

Neurophysiological Effects of Drugs of Abuse on Dopamine Neurons In Vitro during Development
pp. 29-29(1)
Authors: Mereu G.; DeMuro A.; Lilliu V.; Francesconi W.; Berton F.; Casula A.; Vicini S.; Gessa G.L.

Developmental Neuro- and Immunotoxicity of Benzodiazepines
pp. 29-29(1)
Authors: Schlumpf M.; Salili A.R.; Schreiber A.A.; Burgi B.; Butikofer E.E.; Lichtensteiger W.; van Loveren H.

Neurobehavioral Changes Produced by Prenatal Exposure to Carbon Monoxide, A Constituent of Cigarette Smoke
pp. 29-29(1)
Authors: Cuomo V.; Cagiano R.; De Salvia M.A.; Renna G.; Cortese I.; Siro G.; Di Giovanni V.

Cholinergic Therapy Directed at Cognitive Deficits
pp. 29-30(2)
Author: Wesnes K.A.

Muscarinic Partial Agonists in the Symptomatic Treatment of Alzheimer's Disease
pp. 30-30(1)
Authors: Kumar R.; Cedar E.; Clark M.; Loudon J.; McCafferty J.; Hammond L.

Therapeutic Strategies Directed at the Non-Cholinergic Transmitter Systems
pp. 30-30(1)
Authors: Robert P.H.; Aubin-Brunet V.; Beau C.H.; Migneco V.; Darcourt G.

GABA-B Receptors in Memory Processes
pp. 30-30(1)
Authors: Frostl W.; Mickel S.; Mondadori C.; Olpe H.; Bittiger H.

Cognitive Disorders in HIV Infection
pp. 30-31(2)
Author: Brew B.J.

The Mechanisms and Clinical Relevance of HIV Associated Brain Damage
pp. 31-31(1)
Author: Everall I.P.

NMR Spectroscopy as a Tool for In Vivo Detection and Monitoring of Progress of HIV CNS Disease
pp. 31-31(1)
Authors: Fein G.; Meyerhoff D.; Weiner M.

The Epidemiology of Psychiatric Disorders in HIV Infection: Depression, Mania and Dementia
pp. 31-31(1)
Authors: Lyketsos C.G.; Treisman G.J.

Treatment of Neuropsychiatric Disorders Associated with HIV and AIDS
pp. 31-31(1)
Authors: Treisman G.J.; Fishman M.; McHugh P.R.; Lyketsos C.G.

Neuropeptides in Human Sleep Regulation
pp. 31-32(2)
Authors: Steiger A.; Antonijevic I.; Bohlhalter S.; Frieboes R.-M.; Schier T.; Holsboer F.

Benzodiazepines Versus Newer Hypnotics
pp. 32-32(1)
Author: Monti J.M.

GABA Mechanisms in Sleep Deprivation and Their Relevance to Depression
pp. 32-32(1)
Authors: Holsboer-Trachsler E.; Hemmeter U.; Seifritz E.

Cholinergic Mechanisms in Sleep and Depression
pp. 32-32(1)
Authors: Mathias B.; Fritz H.; Dieter R.

SSRIS, TCAS and Augmentation Therapies -- Exploring Mechanisms by Acute and Chronic Sleep Effects
pp. 32-32(1)
Authors: Wilson S.J.; Bell C.J.; Coupland N.J.; Nutt D.J.

Will Novel Antipsychotics be the next Standard of Care for Patients with Schizophrenia: A Worldwide Report on Risperidone
pp. 33-33(1)
Author: Grebb J.

First Episode Psychosis: Diagnosis, Treatment and the Role of New Antipsychotics
pp. 33-33(1)
Author: Remington G.

SDA Antipsychotics -- from Theory to Clinical Practice: Lessons from PET Neuroimaging
pp. 33-33(1)
Author: Kapur S.

Clinical Experience of Novel Antipsychotics the Role of Novel Antipsychotics for the Many Phases of Schizophrenia
pp. 33-33(1)
Author: Keks N.A.

Managing Elderly Patients with Psychotic and Behavioural Disturbances in Dementia.
pp. 33-34(2)
Author: Finkel S.I.

The Role of the Suprachiasmatic Nuclei (SCN) as a Biological Clock: Effects of Melatoninergic Substances
pp. 34-34(1)
Authors: Turek F.W.; Reeth O.V.

Animal Models of Circadian Disorders and Their Treatment with Chronobiotics
pp. 34-34(1)
Author: Redman J.R.

Sleep and Mood Disorders: Relationship to Circadian Rhythms
pp. 34-34(1)
Authors: Wehr T.A.; Leibenluft E.; Schwartz P.J.; Turner E.H.; Rosenthal N.E.

Does Bright Light Treatment for Winter Depression Work Better Than a Placebo?
pp. 34-34(1)
Authors: Eastman C.I.; Young M.A.; Fogg L.F.

Circadian Phase Disorders and Psychiatry
pp. 35-35(1)
Authors: Lewy A.; Bauer V.; Hughes R.; Cutler N.; Sack R.

Long Term Outcome of Fluoxetine Treatment in Elderly Depressed Patients
pp. 35-35(1)
Authors: McWilliam C.; Hanna M.

Clinical Efficacy of Paroxetin in Old Age Depression
pp. 35-35(1)
Authors: Wittgens W.; Beine K.

Inter-Observer Reliability among GPs in a Controlled Clinical Study on Geriatric Depression
pp. 35-35(1)
Authors: Lauritzen L.; Korner A.; Pedersen T.; Bayer L.

Comparison of Sertraline and Fluoxetine in Depressed Geriatric Outpatients: Plasma Levels and Efficacy
pp. 35-35(1)
Authors: Newhouse P.; G. K.; Richter E.

Effect of Gender, Age and Smoking on Doses and Plasma Levels of Neuroleptics in Schizophrenia
pp. 36-36(1)
Authors: Salokangas R.K.R.; Taiminen T.; Syvalahti E.; Saarijarvi S.; Lehto H.; Niemi H.; Ahola V.

Age Effect on the Plasma Levels of Various Psychotropic Drugs
pp. 36-36(1)
Authors: Kamimura M.; Yamaguchi N.; Morokawa Y.; Ohta T.; Fujimaki H.; Aoba A.

Effect of Age, Gender and Food on the Pharmacokinetics of Flesinoxan
pp. 36-36(1)
Authors: Van Harten J.; Boon C.; Strobel W.

Sertraline and Nortriptyline: Heart Rate, Cognitive Improvement and Quality of Life in Depressed Elderly
pp. 36-36(1)
Authors: McEntee W.; G. K.; Richter E.

No Age-Related Change in Platelet Tritiated Paroxetine Binding in Humans
pp. 36-37(2)
Authors: Marazziti D.; Palego L.; Dell'Osso L.; Fancelli M.; Rossi A.; Lucacchini A.; Cassano G.B.

Lack of Pharmacokinetic Interaction Between Buspirone and Haloperidol in Schizophrenic Patients
pp. 37-37(1)
Authors: Jann M.W.; H. F.H.; T. P.C.; J. S.C.; D. J.J.; S. K.L.; Y. W.F.L.; C. P.C.; W. H.C.

Effect of Rifampin on Plasma Concentrations and Clinical Responses of Haloperidol in Schizophrenics
pp. 37-37(1)
Authors: J. I.W.; Y. H.K.; J. C.S.; J. G.S.; S. G.S.

The Quantitative Analysis of a Haloperidol Derivative and Its Neurotoxic Metabolites in Baboons
pp. 37-37(1)
Authors: Avent K.; Van der Schyf C.; Eyles D.; Castagnoli N.; Pond S.

Mitochondrial Toxicity of Haloperidol and its Metabolites
pp. 37-37(1)
Authors: McLennan H.R.; Esposti M.D.; McGrath J.J.; Pond S.M.

Multiple Dose Pharmacokinetics and Dose Proportionality Study of 'Seroquel' (ICI 204,636) in Male Schizophrenic Patients
pp. 38-38(1)
Authors: Y. W.J.W.; Ewing B.J.; Fabre L.F.; Thyrum P.T.; Yeh C.

The Effect of Ziprasidone on Steady-State Pharmacokinetics of a Combined Oral Contraceptive
pp. 38-38(1)
Authors: Muirhead G.J.; Holt P.R.; Oliver S.; Harness J.; Anziano R.J.

Single and Multiple Dose Pharmacokinetics of Ziprasidone in Healthy Males
pp. 38-38(1)
Authors: Wilner K.D.; Hansen R.A.; Johnson A.C.; Miceli J.J.; Apseloff G.; Gerber N.

The Effects of Ziprasidone on Steady-State Lithium Levels and Renal Clearance of Lithium
pp. 38-38(1)
Authors: Wilner K.D.; Anziano R.J.; Tensfeldt T.G.; Pelletier S.M.; Apseloff G.; Gerber N.

Specific HPLC Method for Risperidone and 9-Hydroxy Risperidone Therapeutic Monitoring
pp. 38-39(2)
Authors: Balant-Gorgia E.A.; Balant L.P.

Reversible Metabolism of Clozapine and Clozapine N-Oxide
pp. 39-39(1)
Authors: W. H.C.; S. K.L.; Lane H.Y.; F. C.W.; W. H.H.; Y. W.F.L.; M. W.J.

Kinetics/Dynamics of Midazolam and Two New Benzodiazepines During First Administration in Man. I: RO 48-6791
pp. 39-39(1)
Authors: Dingemanse J.; Roncari G.; Schoemaker H.C.; Cohen A.F.; Van Gerven J.M.A.

Kinetics/Dynamics of Midazolam and Two New Benzodiazepines During First Administration in Man. II: RO 48-8684
pp. 39-39(1)
Authors: Van Gerven J.M.A.; Roncari G.; Schoemaker H.C.; Cohen A.F.; Dingemanse J.

Low Kinetic Interaction Potential of Flesinoxan in Man
pp. 39-39(1)
Authors: Van Harten J.; May S.; Baedeker C.

No Kinetic or Dynamic Interaction Between Flesinoxan and Fluoxetine
pp. 40-40(1)
Authors: Van Harten J.; Wesnes K.; Strobel W.

The Influence of Morning and Evening Dosing on the Pharmacokinetics of Flesinoxan
pp. 40-40(1)
Authors: Van Harten J.; Bosschaert M.A.R.

Sumatriptan in Plasma by HPLC with Coulometric Detection; Effect of Paroxetine Treatment on Plasma Sumatriptan Concentrations
pp. 40-40(1)
Authors: Franklin M.; Odontiadis J.; Clement E.M.; Cowen P.J.; Wing Y.K.

Sertraline and P4503A3/4
pp. 40-40(1)
Authors: Harvey A.; Preskorn S.; Lane R.; Wilner K.

Multiple Dose Pharmacokinetics of Sertraline in Subjects with Varying Degrees of Hepatic Impairment
pp. 40-41(2)
Authors: Wilner K.D.; Everson G.; Foulds G.H.; Hansen R.A.; Shrestra R.; McKinley C.; McClain C.J.

Multiple Dose Pharmacokinetics of Sertraline in Subjects with Varying Degrees of Renal Impairment
pp. 41-41(1)
Authors: Wilner K.D.; Baris B.A.; Foulds G.H.; Anziano R.J.; Berl T.; Ziegler M.G.

Safety and Pharmacokinetics of Sertraline in Japanese Subjects
pp. 41-41(1)
Authors: Kamijima K.; Miyaoka H.; Iwanami A.; Tadokoro C.; Otsubo T.; Oyamada S.

Pharmacokinetic Profile of Mirtazapine
pp. 41-41(1)
Authors: Timmer C.; Voortman G.; Delbressine L.

Amitriptyline and Nortriptyline: Are Plasma Levels after First Dose Predictive for Therapeutical Efficacy?
pp. 41-41(1)
Authors: Stuppaeck C.H.; Whitworth A.B.; Fleischhacker W.W.

Clomipramine and Obsessive-Compulsive Disorder: Serum Levels and Outcome
pp. 41-41(1)
Authors: Gorenstein C.; Marcourakis T.; Bernik M.; Lotufo-Neto F.

Clomipramine and Panic Disorder: Serum Levels and Clinical Improvement
pp. 42-42(1)
Authors: Marcourakis T.; Gorenstein C.; Ramos R.T.

Paroxetine and Fluoxetine Plasma Concentrations and CYP2D6 Inhibition
pp. 42-42(1)
Authors: Lam Y.W.F.; Riesenman C.L.; Ereshefsky L.

SSRIs and Inhibition of the Cytochrome P4502D6 Isoenzyme
pp. 42-42(1)
Authors: Harvey A.; Lane R.

Cytochrome P-450 Isozymes and N-Demethylation of Citalopram Enantiomers In Vitro: Clinical Significance?
pp. 42-42(1)
Authors: Rochat B.; Amey M.; Raumann P.; Gillet M.

Concentrations of the Enantiomers of Trimipramine and its Metabolites in CYP2D6 and CYP2C19 Phenotyped Patients
pp. 42-43(2)
Authors: Eap C.B.; Koeb L.; Amey M.; Baumann P.

Plasma Alpha-One Acid Glycoprotein (AAG) and Halo-Peridol (H) Concentrations in Schizophrenic Patients
pp. 43-43(1)
Authors: Augustin B.G.; Jann M.W.; Crabtree B.L.; Pitts W.M.; Carter J.G.

An Association Study between the ADH2 Gene, the ALDH2 Gene and Alcoholism
pp. 43-43(1)
Authors: Kono Y.; Yoneda H.; Sakai T.; Imamichi H.; Uchida A.; Suzuki K.; Mizoi Y.

5-HT1A Receptors, Alcoholism and Suicidal Behavior
pp. 43-43(1)
Authors: Pitchot W.; Ansseau M.; Moreno A.G.; Hansenne M.

Risperdal Reduces Alcohol Use in Dual Disabled Schizophrenia Patients
pp. 43-43(1)
Author: C. C.H.

Acamprosate in the Relapse Prevention of Alcohol Dependence
pp. 43-44(2)
Authors: Whitworth A.B.; Fleischhacker W.W.

Adrenal Gland Enlargement Resulting from Hyperactivity of the Pituitary-Adrenocortical System in Alcoholics
pp. 44-44(1)
Authors: Ida Y.; Shirao I.; Tsujimaru S.

Treatment of Alcohol Withdrawal Delirium and Changes in Monoamine
pp. 44-44(1)
Authors: Uchimura N.; Nakamura J.; Tsuchiyama Y.; Nakazawa Y.; Yamada S.; Ohshima H.; Ohshima M.

Acamprosate Effect on Changes of Transferrin Levels in Ethanol Preferring and Non-Preferring Rats
pp. 44-44(1)
Authors: Mikolajczak P.; Okulicz-Kozaryn I.; Kaminska E.; Sobieska M.

Glycine/NMDA Antagonists Reduce Amphetamine Disruptions in Prepulse Inhibition in the Rat
pp. 44-44(1)
Authors: Bristow L.J.; Cook G.P.; Saywell K.L.

Blockade of Brain Serotoninergic Receptors Deteriorates Amphetamine-Induced Self-Stimulation in Rats with Lesion of Medial Prefrontal Cortex
pp. 45-45(1)
Authors: Varavka S.G.; Shabanov P.D.; Lebedev A.A.

Effects of Ritanserin on Methamphetamine-Induced Sensitization
pp. 45-45(1)
Authors: Tanaka T.; Watanabe S.; Suzuki M.; Nagata E.; Wakatabe H.; Ishigooka J.; Murasaki M.; Miura S.

Decrease in Calmoduin mRNA Level of Rat Hippocampus after Repeated Methamphetamine Treatment
pp. 45-45(1)
Authors: Shimizu Y.; Akiyama K.; Ishihara T.; Fujiwara Y.; Kuroda S.

Effect of Behavioral Sensitization of Amphetamine on Schedule-Induced Polydipsia (SIP) in Rats
pp. 45-45(1)
Authors: C. S.T.; N. K.H.; T. H.Y.

Ecstasy (MDMA): Mood Effects in Recreational Polydrug Users
pp. 45-45(1)
Author: Parrott A.C.

5-HT Uptake Inhibitors Attenuate the Neurochemical Effects of 3,4 Methylenedioxymethamphetamine
pp. 45-46(2)
Authors: Harkin A.J.; Kelly J.P.; Leonard B.E.

Chronic Treatment with Sulpiride Enhances NMDA-Induced CA²⁺ Influx in Cultured Rat Cortical Neurons
pp. 46-46(1)
Authors: Kagaya A.; Yokota N.; Oyamada T.; Takebayashi M.; Hayashi T.; Furutani M.; Yamawaki S.

Sedative Effect of Acamprosate and Its Influence on Chosen Memory Tasks in Two Different Aged Rats
pp. 46-46(1)
Authors: Okulicz-Kozaryn I.; Mikolajczak P.; Kaminska E.; Szczawinska K.

Mirtazapine vs Tricyclic Antidepressants: An Overview of Efficacy Data
pp. 46-46(1)
Authors: Sitsen A.; Kremer C.; Slinning H.

Mirtazapine vs Tricyclic Antidepressants in the Treatment of Severely Depressed Patients
pp. 46-46(1)
Authors: Zivkov M.; Muhring A.

Efficacy of Mirtazapine vs Clomipramine in Severely Depressed, Hospitalized Patients
pp. 46-47(2)
Author: Peyron E.

Safety of Mirtazapine in Overdose
pp. 47-47(1)
Authors: Zivkov M.; Kremer C.M.E.; Hoes M.

Treatment with Mirtazapine is not Related to Complaints of Sexual Dysfunction
pp. 47-47(1)
Authors: Rekers H.; Kremer C.; Zivkov M.

Mirtazapine Lacks Typical SSRI-Related Adverse Effects
pp. 47-47(1)
Authors: Rekers H.; Kremer C.; Zivkov M.

Efficacy of Mirtazapine in Moderate and Severe Depression
pp. 47-47(1)
Authors: Pinder R.; Kremer C.

Patterns of Mood Improvement with Mirtazapine
pp. 47-48(2)
Authors: Kremer C.M.E.; Zivkov M.

Nefazodone vs. Sertraline in Outpatients with Major Depression: Focus on Efficacy, Tolerability, and Effects on Sexual Function and Satisfaction
pp. 48-48(1)
Authors: Shrivastava R.K.; Feiger A.; Kiev A.; Wisselink P.G.

Efficacy of Nefazodone Versus Placebo in a Double-Blind Trial of Depressed Inpatients
pp. 48-48(1)
Authors: Feighner J.; Bennett M.; Roberts D.; D'Amico F.; O'Brien K.

A Double-Blind Comparison of Milnacipran and Imipramine in Depressive Patients
pp. 48-48(1)
Authors: Matsubara R.; Onodera I.; Ito K.; Okada F.; Asano Y.

Comparative Study of Moclobemide & Clomipramine in the Treatment of Mild Forms of Depression
pp. 48-48(1)
Authors: Krsmanovic M.; Miljevic C.; Jasovic M.; Crnobaric C.

Sulpiride Augmentation in Refractory Depression
pp. 48-49(2)
Authors: Stankovic Z.; Zivkovic-Milovanovic D.; Bugarski-Kirola D.; Damjanovic A.

Efficacy of Combined Lithium/TCAs and Lithium/SSRIs Therapy in Major Depressive Disorder
pp. 49-49(1)
Authors: Timotijevic I.; Zdravkovic M.; Miljkovic B.; Pokrajac M.

Combined Cognitive-Behavioral and Pharmacotherapy in Refractory Depression
pp. 49-49(1)
Author: Strauss W.H.

Gepirone Extended Release (ER) Treatment of Outpatients with Major Depression -- A Dose Response Study
pp. 49-49(1)
Authors: Cohn C.; Fabre L.

Cortisol Synthesis Inhibition: A New Treatment Strategy for Depression
pp. 49-49(1)
Authors: Thakore J.H.; Dinan T.G.

Antidepressive Properties of Indeloxazine Hydrochloride, a Cerebral Activator
pp. 49-49(1)
Authors: Yamamoto M.; Suzuki M.; Yamaguchi T.; Ozawa Y.; Yamaguchi T.

First Open Study with New Antidepressant LY248686 (Duloxetine) for Depression in Japan
pp. 50-50(1)
Authors: Ishigooka J.; Murasaki M.

Predictors of Outcome for Long-Term Treatment
pp. 50-50(1)
Author: Hirschfeld R.M.A.

Serotonergic Dysregulation in Dysthymia
pp. 50-50(1)
Authors: Steiner M.; Dunn E.; Coote M.; Browne G.

A Randomized, Double-Blind Placebo-Controlled Study: Venlafaxine ER Capsules in Major Depression
pp. 50-50(1)
Authors: Derivan A.; Aguiar L.; Rudolph R.; Entsuah R.

Effects of Chronic Administration of Fluvoxamine on Extracellular Levels of Serotonin in the Rat Hippocampus In Vivo
pp. 50-51(2)
Authors: Tajima O.; Nara K.; Sasaki N.; Murata S.; Kogure M.; Takemasa K.

Multiple 5-HT Receptor Subtypes Regulate [³H]5-HT Release in Terminal Projection Areas: Superfusion Studies in Rat and Mice Brain
pp. 51-51(1)
Authors: Pineyro G.; Hen R.; Blier P.

Effect of a Combination of Befloxatone and a 5HT_1A Receptor Antagonist on Rat Cortical Serotonin Release
pp. 51-51(1)
Authors: Curet O.; Lourdelet J.; Damoiseau G.; Avenet P.; Depoortere H.; Scatton B.

Anti-Aggressive Effects of Alnespirone (S-20499), a Potent 5-HT_1A Receptor Agonist, in Wild-Type Rats
pp. 51-51(1)
Authors: Lesourd M.; Mocaer E.; De Boer S.F.; Koolhaas J.M.

Electrophysiological Effect of Alnespirone (S-20499) on the Rat Locus Coeruleus -- Comparison with Buspirone
pp. 51-51(1)
Authors: Schmitt P.; Souliere F.; Mocaer E.; Lesourd M.; Chouvet G.

Effects of Alnespirone (S 20499) in the Depression Model (Unavoidable Aversive Light Stimulus Test) in Rats
pp. 52-52(1)
Authors: Messaoudi M.; Tricoire A.; Jung P.H.; Desor D.; Mocaer E.; Lesourd M.

Effect of the Potential Anxiolytic Drug (+) S-20499 in the Olfactory Bulbectomised Rat Model
pp. 52-52(1)
Authors: McGrath C.; Norman T.; Burrows G.

Behavior-Enhancing Effects of 5HT1A Agonists and 5HT2 Antagonists on a Progressive Ratio Schedule
pp. 52-52(1)
Author: Leander J.D.

Chirality and the SSRIS
pp. 52-52(1)
Author: Lane R.

(+)-Mirtazapine and (+)-Desmethylmirtazapine Levels in Rat Brain in Relation to in Vivo Blockade of ₂ Receptors
pp. 52-53(2)
Authors: Broekkamp C.L.E.; Delbressine L.P.C.; Rijk H.W.; Van De Vorstenbosch C.G.

Mirtazapine Stimulus Properties Reveal Indirect 5-HT_1A Receptor Activation
pp. 53-53(1)
Authors: Berendsen H.H.G.; Broekkamp C.L.E.

The Neurochemical and Behavioural Effects of the Isomers of Mirtazapine in Normal Rats
pp. 53-53(1)
Authors: McGrath C.; Norman T.; Burrows G.

Effect of Chronic Antidepressant Treatment in the Olfactory Bulbectomised Rat Model of Depression
pp. 53-53(1)
Authors: McGrath C.; Norman T.; Burrows G.

Effect of Nicotine Treatment, Pre- and Post Surgery, on the Behaviour of the Olfactory Bulbectomised Rat
pp. 53-53(1)
Authors: McGrath C.; Norman T.; Burrows G.

Sertraline Did Not Affect Monoamine Receptors and Adenylate Cyclase Activity in Rat Brain
pp. 54-54(1)
Authors: Tadokoro C.; Kiuchi Y.; Ota A.; Oguchi K.; Kamijima K.

Endogenous Mono-ADP-Ribosylation in the Hippocampus of Amygdaloid Kindled Rat
pp. 54-54(1)
Authors: Suzuki K.; Iwasa H.; Kikuchi S.; Sato T.; Morinaga N.; Noda M.

Importance of Protein Synthesis for the Development of Chemical Kindling
pp. 54-54(1)
Authors: Grecksch G.; Becker A.

Effects of Verapamil and Ethaverine on the Behavioral Despair Test in Rats
pp. 54-54(1)
Authors: Kim Y.H.; Lee S.K.; Kim J.H.; Gang T.M.; Kim K.T.

Antidepressant-Like Effects of the I2 Ligands Idazoxan and 2-BFI in the Rat Porsolt Test
pp. 54-54(1)
Authors: Jackson H.C.; Mirza N.R.; Nutt D.J.; Jordan S.; Handley S.L.

L Deprenyl Versus Moclobemide in Animal Model of Depression -- ''Swim Test''
pp. 54-55(2)
Authors: Milijec C.D.; Djorgovic D.; Damjanovic A.; Cmobaric C.; Paunovic V.R.

Effects of Mirtazapine and Other Clinically Active Antidepressants in the DRL-72
pp. 55-55(1)
Authors: Andrews J.S.; Bloks S.; Jansen J.H.M.

Effects of Selective Antidepressants on the Sensitivity of Central Adrenergic Receptors
pp. 55-55(1)
Authors: Babinski T.; Totic S.; Marinkovic D.; Paunovic V.R.

Tricycles and SSRIS Enhance Adenylate Cyclase and cAMP-Related Behaviors in Rat
pp. 55-55(1)
Authors: Maeda H.; Ozawa H.; Kamata H.; Toki S.; Saito T.; Takahata N.

A Comparison of Phenelzine and its N-Acetylated Analogue in the Elevated Plus-Maze Test
pp. 55-55(1)
Authors: Baker G.B.; Treit D.; Paslawski T.M.; George M.; Coutts R.T.

HT-90B, a Putative Anxiolytic with Potent Antidepressive Activity
pp. 56-56(1)
Authors: Miyauchi T.; Inagawa K.; Uchida H.; Takashima C.

The Effect of Lithium Potentiation of Antidepressants in Chronic Mild Stress Model of Depression in Rats
pp. 56-56(1)
Authors: Sluzewska A.; Szczawinska K.

Increase of GABA-B Responses by Carbamazepine as a Mechanism of Action in Affective Disorders
pp. 56-56(1)
Authors: von Wegerer J.; Walden J.

Behavioural & Cognitive Effects of Stimulant & Non Stimulant Drugs in Childhood Attention Deficit Disorder
pp. 56-56(1)
Authors: Orgill A.; Serfontein S.

Exploratory Eye Movements in Child Patients with Mental Disorders
pp. 56-57(2)
Authors: Matsushima E.; Ohkura T.; Ichikawa H.; Yamada S.; Takamizawa M.; Nakane A.; Toru M.

Body Satisfaction in a Group of Obese Adolescents
pp. 57-57(1)
Authors: Morosin A.; Molinari E.; Ragazzoni P.

Satisfaction with Life, Anxiety and Eating Attitude in a Sample of Obese Women
pp. 57-57(1)
Authors: Ragazzoni P.; Molinari E.; Morosin A.

Serotonin-Induced Platelet Calcium Response in Eating Disorders
pp. 57-57(1)
Authors: Okamoto Y.; Okamoto Y.; Kagaya A.; Kugaya A.; Uchitomi Y.; Yamawaki S.

Menstrual Cycle Effects in Women with Premenstrual Syndrome
pp. 57-57(1)
Authors: Evans S.; Haney M.; Levin F.; Foltin R.; Fischman M.

Maprotiline for Depression during Menopause: A Philippine Menopause Clinic Experience
pp. 57-58(2)
Authors: Obillo E.; Eleazar J.; Demeterio J.

Cortisol and Maternal Attraction to Infant Odour
pp. 58-58(1)
Authors: Steiner M.; Coote M.; Tran A.; Corter C.; Fleming A.

Establishing a Liaison Network Service for Postnatal Depression in the Primary Care Setting
pp. 58-58(1)
Author: Blankley G.

The Course of Primary and Secondary Negative Symptoms in a Controlled Trial with Olanzapine
pp. 58-58(1)
Authors: Tollefson G.D.; Sanger T.M.; Beasley C.M.

Olanzapine Versus Placebo, Results of the United-States Double-Blind Olanzapine Trial
pp. 58-58(1)
Authors: Beasley C.; Tran P.; Satterlee W.; Tollefson G.; Y. L.; Kuntz A.; Bradley P.; Paul S.

Acute and Long-Term Results of the Dose Ranging Double-Blind Olanzapine Trial
pp. 58-59(2)
Authors: Tran P.; Beasley C.; Tollefson G.; Crawford A.; Dellva M.; Gusman S.; Wood A.

Acute and Long-Term Results of the North American Double-Blind Olanzapine Trial
pp. 59-59(1)
Authors: Tran P.; Beasley C.; Tollefson G.; Dellva M.; Hamilton S.; Van Ostrand R.; Paul S.

Olanzapine Versus Haloperidol: Acute Results of the Multi-Center International Trial
pp. 59-59(1)
Authors: Tran P.; Beasley C.; Street J.; Tamura R.; Dellva M.A.; Graffeo K.; Krueger J.; Tollefson G.

Olanzapine Versus Haloperidol: Long-Term Results of the Multi-Center International Trial
pp. 59-59(1)
Authors: Beasley C.; Tran P.; Beuzen J.N.; Tamura R.; Dellva M.A.; Bailey J.; Krueger J.; Tollefson G.

Clinical Efficacy and Safety of Olanzapine in Japanese Schizophrenics
pp. 59-60(2)
Authors: Ishigooka J.; Miura S.; Murasaki M.; Kudo Y.

The Efficacy of Zuclopenthixol Acetate in the Treatment of Psychtic Patients
pp. 60-60(1)
Authors: Dilbaz N.; Guz H.; Boyam G.

Clinical Experience with Zuclopentixol in Twenty-Five Acute Schizofrenic Patients
pp. 60-60(1)
Authors: Vilaprino J.; Galeno R.; Kotlik S.; Gris E.; Guzzo C.; Daneo A.

A Controlled Double Blind Study of Zuclopenthixol Acetate Compared with Clothiapine in Acute Psychosis Including Mania and Exacerbation of Chronic Psychosis
pp. 60-60(1)
Authors: Uys H.; Berk M.

Efficacy of L-Sulpiride in the Treatment of Disorganization in Acutely Relapsed Schizophrenics
pp. 60-60(1)
Authors: Guazzelli M.; Gemignani A.; Pietrini P.; Starnini S.; Bertolino A.; Bertolino A.; Casacchia M.; Fiori L.

Amisulpride in the Treatment of Acute Schizophrenia: A Double-Blind Comparison with Haloperidol
pp. 60-61(2)
Authors: Boyer P.; Turjanski S.; Fleurot O.

Amisulpride in the Treatment of Acute Episodes of Schizophrenia
pp. 61-61(1)
Authors: Amisulpride Study Group; Puech A.J.; Turjanski S.; Fleurot O.

Efficacy and Safety of Three Doses of Sertindole and Haldol in Schizophrenic Patients
pp. 61-61(1)
Authors: Tamminga C.; Mack R.; Zborowski J.; Morris D.; Sebree T.; Wallin B.

Dose Ranging Study Comparing 4 Doses of Sertindole and 1 Dose of Haloperidol in Schizophrenic Patients
pp. 61-61(1)
Authors: Hale A.; van der Burght M.; Friberg H.H.; Wehnert A.

Two Open-Label, Long-Term Safety Studies of Sertindole
pp. 61-62(2)
Authors: Daniel D.; Holgate K.; Sebree T.; Staser J.; Schmitz P.; Wallin B.

The 'Organic' Basis of Late-Onset Schizophrenia
pp. 62-62(1)
Authors: Sachdev P.; Brodaty H.; Rose N.; Haindl N.; Frayter C.; Kitchener P.

Comorbid Mood Disturbance in Schizophrenia
pp. 62-62(1)
Authors: Tollefson G.D.; Yu Y.

Anhedonia and Depression in Chronic Schizophrenia: Distinct or Overlapping Constructs?
pp. 62-62(1)
Authors: Loas G.; Boyer P.; Noisette C.; Legrand A.

The Relationship between Negative Symptoms and Depression in Schizophrenia
pp. 62-63(2)
Authors: Addington D.; Addington J.

Negative Symptoms and Neuropsychologic Dysfunction are Independent Features of Schizophrenia
pp. 63-63(1)
Authors: Maltez J.; Guerreiro M.; Cavaglia F.; Matos-Pires A.; Botelho M.

Panic Attacks in Chronic Schizophrenia a Complication of Long-Term Antipsychotic Medication
pp. 63-63(1)
Authors: Higuchi H.; Kamata M.; Yoshimoto M.; Yoshida K.; Hishikawa Y.

Clozapine in Treatment-Resistant Schizophrenic Patients: Clinical, Neuropsychological and Neuroanatomical Correlates of Outcome
pp. 63-63(1)
Authors: Shriqui C.L.; Annable L.; Bouchard G.; Grondin P.; Dufour M.

Correlations Between Neurophysiological Abnormalities and Brain Morphological Changes in Schizophrenia
pp. 63-63(1)
Authors: Tanabe E.; Takahashi S.; Xia M.L.; Sakai T.; Matsuura M.; Kojima T.; Matsushima E.; Obayashi S.

Impairment of Spatial Context Memory in Schizophrenia
pp. 64-64(1)
Authors: Danion J.M.; Rizzo L.; Van Der Linden M.; Rohmer J.G.; Grange D.

Eye Movement Studies on Schizophrenics and their Parents
pp. 64-64(1)
Authors: Xia M.L.; Takahashi S.; Tanabe E.; Matsuura M.; Kojima T.; Matsushima E.

Eye Movements Made During the Performance of a Maze Test in Schizophrenic Patients
pp. 64-64(1)
Authors: Ando H.; Matsushima E.; Ando K.; Kojima T.; Shimazono Y.

A Checklist for Assessment of Treatment in Schizophrenic Syndromes: Interscale Validity and Interreter Reliability
pp. 64-64(1)
Authors: Lindstrom E.; Ekselius L.; Jedenius E.; Almqvist A.; Wieselgren I.M.

Inter-Rater Reliability of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS)
pp. 64-64(1)
Authors: Inada T.; Yagi G.; Gardos G.

Neurocognitive Subtypes of Schizophrenia According to Performances at the Verbal Fluency Test
pp. 65-65(1)
Authors: Robert P.H.; Thauby S.; Migneco V.; Chaix I.; Benoit M.; Darcourt G.

The Attribution of Intentionality, Causality and Disposition by Deluded Patients
pp. 65-65(1)
Authors: Done D.J.; Millard V.; Pattinson H.A.; Papanastasiou M.

An Inventory of Chronic, Mentally Disabled Schizophrenic Outpatients
pp. 65-65(1)
Authors: Flyckt L.K.; Taube A.; Edman G.V.; Jedenius E.

Serotonin in Platelets and Whole Blood in Schizophrenic Patients
pp. 65-65(1)
Authors: C. H.T.; H. S.L.

Risperidone vs. Haloperidol in the Treatment of Schizophrenia: A Meta-Analysis Comparing their Efficacy and Safety
pp. 65-66(2)
Authors: De Oliveira I.; De Miranda A.; De Sena E.; Pereira E.; Ribeiro M.; Silva E.

Recent Advances in the Therapeutics of Schizophrenia: Is Dopamine still Relevant?
pp. 67-67(1)
Author: Carlsson A.

Neuropeptides and their Receptors
pp. 67-67(1)
Author: Furness J.B.

The Role of In Vivo Amygdala Dopamine to Cocaine Self-Administration Behavior
pp. 67-67(1)
Authors: Hurd Y.L.; McGregor A.

Gamma-Hydroxybutyric Acid Alters Intravenous Cocaine Self-Administration in Rats
pp. 67-67(1)
Authors: Martellotta M.C.; Cossu G.; Fattore L.; Fratta W.

Occupation of D1, D2 and 5HT-2 Receptors and Behavioural Sensitization to Cocaine
pp. 67-68(2)
Author: Martin-Iverson M.T.

Smoked or I.V. Cocaine Binges in Humans: Is There a ''Crash''?
pp. 68-68(1)
Authors: Foltin R.W.; Fischman M.W.

Determinants of Withdrawal in a Methadone Maintenance Population
pp. 68-68(1)
Authors: White J.M.; Dyer K.R.; Bochner F.; Menelaou A.; Somogyi A.A.

A Rapid Discontinuation of Opiates and Benzodiazepines in Dependent Patients
pp. 68-68(1)
Authors: Bennie E.H.; Poole N.

Lofexidine in the Treatment of Heroin Withdrawal -- A Comparative Study with Clonidine
pp. 68-68(1)
Authors: S. K.L.; L. W.S.; C. J.T.; W. H.H.

Neuropeptide Y Attenuates Naloxone-Precipitated Morphine Withdrawal in Rats
pp. 68-69(2)
Authors: Woldbye D.P.D.; Bolwig T.G.

Striatal Adenosine-Dopamin Modulation in Morphine Dependence and Withdrawal
pp. 69-69(1)
Authors: Liu Y.-P.; Bau D.-T.; Hwang N.-K.; Chen P.-M.; Liu W.-J.; Tung C.-S.

Clocinnamox Inhibits Heroin-Stimulated Nucleus Accumbens Dopamine Overflow
pp. 69-69(1)
Authors: Zernig G.; Fibiger H.C.

Panic Attack as an Epi-Phenomenon of the Phobic-Obsessive-Compulsive Disease
pp. 69-69(1)
Author: Hejaij C.R.

Biological and Psychopathological Comparison of OCD and Tourette Syndrome
pp. 69-70(2)
Authors: Muller N.; Putz A.; Riedel M.; Kathmann N.; Straube A.

Fluoxetine Treatment of Acral Lick Dermatitis in Dogs: A Placebo Controlled Randomised Double Blind Trial
pp. 70-70(1)
Authors: Wynchank D.; Berk M.

Proton Magnetic Resonance Spectroscopy in Obsessive Compulsive Disorder
pp. 70-70(1)
Authors: Ebert D.; Speck O.; Konig A.; Rasche-Rauchle H.; Berger M.; Hennig J.; Hohagen F.

Cerebral Blood Flow and WCST in OCD
pp. 70-70(1)
Authors: Lucey J.V.; Burness C.; Costa D.C.; Pilowsky L.S.; Marks I.M.; Ell P.J.; Kerwin R.W.

Serotonergic Function in Obsessive-Compulsive Disorder
pp. 70-70(1)
Authors: Monteleone P.; Catapano F.; Di Martino S.; Maj M.

OCD: Comparisons of SRI Treatment
pp. 70-70(1)
Author: Pigott T.A.

Use of Citalopram, a Serotonin Selective Reuptake Inhibitor, in OCD
pp. 70-70(1)
Authors: Stein D.; Maud C.; Bouwer M.B.

Long Term Course of Tardive Dyskinesia
pp. 71-71(1)
Authors: Gardos G.; Cole J.O.; Samson J.A.; Haskell D.S.; Boling L.A.; Waternaux C.; Kovacs D.

Neuroleptic-Induced Extrapyramidal Symptoms: Factor Structure
pp. 71-71(1)
Authors: Annable L.; Chouinard G.; Ross-Chouinard A.

Gates: A New Instrument for the Clinical and Research Assessment of Neuroleptic-Induced Movement Disorders
pp. 71-71(1)
Author: Lambert T.J.R.

Informing Patients about Tardive Dyskinesia: A Survey of Clinicians' Attitudes
pp. 71-71(1)
Authors: Laugharne J.D.E.; Arcelsus J.; Davies A.

Tardive Dyskinesia and Ethnicity: Review of the Literature
pp. 71-71(1)
Authors: Smith M.; Swartz J.R.; Burgoyne K.; Gadasally R.; Ananth J.

Abnormal Movements in Never Medicated Indian Schizophrenic Patients
pp. 71-72(2)
Authors: McCreadie R.G.; Thara R.

CYP2D6, Genotype, Phenotype and Tardive Dyskinesia
pp. 72-72(1)
Authors: Ananth J.; K. M.L.; Costa J.; Poland R.

A Phosphoinositide Linked Dopamine Receptor Mediates Dyskinetic Jaw Movements in Rats
pp. 72-72(1)
Authors: Rosengarten H.; Friedhoff A.J.

A Double-Blind, Assessment of Carteolol, in the Treatment of Neuroleptic-Induced Akathisia
pp. 72-72(1)
Authors: Aoba A.; Murasaki M.; Kamijima K.; Yagi G.; Komemushi S.; Miura S.

Is Loxapine an 'Atypical' Antipsychotic: A Pet Study of the In Vivo 5-HT₂ AND D₂ Occupancy
pp. 72-72(1)
Authors: Kapur S.; Remington G.; Jones C.; Houle S.; Zipursky R.B.

A Positron Emission Tomography (PET) Activation Study of Major Depression
pp. 73-73(1)
Authors: P. C.; Morris P.L.P.; Egan G.F.; Saling M.; Pipingas A.; Berlangieri S.U.; Fitt G.; Schweitzer I.; Burrows G.D.

Relationship Between D₂ Receptor Occupancy and Plasma Haloperidol: A Pet Study
pp. 73-73(1)
Authors: Kapur S.; Remington G.; Jones C.; Roy P.; Reed K.; Houle S.; Zipursky R.B.

D2-Receptor Imaging in Atypical Neuroleptics
pp. 73-73(1)
Authors: Kasper S.; Tauscher J.; Kufferle B.; Heiden A.; Neumeister A.; Barnas C.; Asenbaum S.; Podreka I.; Brucke T.

Pet Studies of D₁ and D₂ Dopamine Receptors in Schizophrenic Patients
pp. 73-73(1)
Authors: Suhara T.; Kobayashi K.; Sudo Y.; Suzuki K.; Inoue O.; Tateno Y.; Okubo Y.; Terasaki O.; Someya Y.; Sassa T.; Toru M.

A PET Study of Attention and Working Memory: Subspecialisation of Human Prefrontal Cortex
pp. 73-74(2)
Authors: O'Sullivan B.; Large M.; Barrett N.; Karayanidis F.; Michie P.; Smith G.; Watson J.; Kavanagh D.

Risperidone and the Relationship Between D₂ Receptor Occupancy and Plasma Levels
pp. 74-74(1)
Authors: Remington G.; Kapur S.; Jones C.; Zipursky R.; Houle S.

Time Course for Dopamine and Serotonin Receptor Occupancy in the Brain of Schizophrenic Patients Following Dosing with 150 mg 'Seroquel' TID.
pp. 74-74(1)
Authors: Gefvert O.; Lindstrom L.H.; Langstrom B.; Bergstrom M.; Lundberg T.; Yates R.A.

Sleep and Waking during Acute Histamine H₃-Agonist BP 2.94 or H₃-Antagonist Carboperamide (MR 16155) Administration in Rats
pp. 74-74(1)
Authors: Monti J.M.; Jantos H.; Ponzoni A.; Monti D.

Neuropeptide Y Inhibits Hippocampal Seizures and Wet Dog Shakes
pp. 75-75(1)
Authors: Woldbye D.P.D.; Mikkelsen J.D.; Madsen T.M.; Larsen P.J.; Bolwig T.G.

Differentiation of Classical and Novel Antipsychotics Using Animal Models
pp. 75-75(1)
Authors: Skarsfeldt T.; Arnt J.; Hyttel J.; Sanchez C.

Kindling of the Dorsal and the Ventral Hippocampus and it's Effects on Learning Performance in Rats
pp. 75-75(1)
Authors: Becker A.; Letzel K.; Letzel U.; Grecksch G.

Differential Effects of Mirtazapine and Imipramine on Cognitive Performance in Male Long Evans Rats
pp. 75-75(1)
Authors: Andrews J.S.; Jansen J.H.M.

Protective Effects of Anapsos in Rats with Hippocampal Neurodegeneration
pp. 75-75(1)
Authors: Alvarez X.A.; Miguel-Hidalgo J.J.; Lagares R.; Franco A.; Fernandez-Novoa L.; Beyer K.; Lao J.I.; Vecino B.; Cacabelos R.; Diaz J.; Sempere J.M.

The Comparison of Lisinopril and Captopril Activities on Cerebral Blood Flow in SHR Rats
pp. 76-76(1)
Authors: Bobkiewicz-Kozlowska T.; Forjasz-Grus R.

Neuroprotective Effects of Dopamine Receptors Agonists in Cerebral Ischemia
pp. 76-76(1)
Authors: Allain H.; Reymann J.M.; O'Neill M.; Caldwell M.; Leonard B.E.; Bentue-Ferrer D.

Effects of Imidazoline₂ Receptor Ligands on Neuronal Damage in Global Ischaemia in the Rat
pp. 76-76(1)
Authors: Graven J.A.; Conway E.L.

Posttraumatic Stress Disorders Among the Afghanistan War Veterans
pp. 76-76(1)
Authors: Sidorov P.; Lukmanov M.

Twenty-Four-Hour Urinary Monoamine Excretion in Posttrumatic Stress Disorder
pp. 76-77(2)
Authors: Moonyong C.; IlJin J.; MyungHee L.

Influence of Psychotropic Agents on Process of Brain Desadaptation in Emotional Stress States
pp. 77-77(1)
Authors: Nerush P.A.; Koldunov V.V.; Topka E.G.

Regulation of Gene Expression of Catecholamine Synthetic Enzymes in Brain and Periphery of Rats during Stress
pp. 77-77(1)
Authors: Kvetnansky R.; Rusnak M.; Zorad S.; Nankova B.; Sabban E.L.

Serotonin Metabolism and 5-HT1A Receptors in Genetically Defined Fear-Induced Aggression
pp. 77-77(1)
Authors: Popova N.K.; Avgustinovich D.F.

GABA-A Receptor Mediated Antistress Activity of Neurosteroids in Mice
pp. 77-77(1)
Authors: Kulkarni S.K.; Reddy D.S.

Anticonflict Effect of High Doses of Testosterone in Male Wistar Rats
pp. 77-78(2)
Authors: Bing O.; Heilig M.; Kakaoulidis P.; Sundblad C.; Eriksson E.

Social Isolation Increases the Effects of Paroxetine in the Forced Swimming Test
pp. 78-78(1)
Authors: Wongwitdecha N.; Ganpinyo P.; Kasemsook C.

Attenuation of Stress Induced Cortical Dopamine Neurones by L-701,324, a Selective Glycine/NMDA Antagonist is Mediated Via an Interaction with GABAergic Neurones
pp. 78-78(1)
Authors: Barton C.L.; Hutson P.H.

Antisense Studies of Rat Brain GABA_A Receptor Structure and Function in Vivo
pp. 78-78(1)
Authors: Karle J.; Nielsen M.

Surprising Drug Effects on the Circadian Rest-Activity Cycle in Schizophrenia
pp. 78-78(1)
Authors: Haug H.-J.; Reichert U.; Cajochen C.; Nussbaum P.; Wirz-Justice A.

The Effects of Ethanol on the Circadian Rhythms of Locomotor Activity and Body Temperature in Rats
pp. 78-79(2)
Authors: Egami H.; Tsujimaru S.; Ida Y.

Chronobiotic Versus Hypnotic Properties of Melatonin
pp. 79-79(1)
Authors: Wirz-Justice A.; Armstrong S.M.

Effects of H-CRH on Sleep and Body Temperature Rhythms
pp. 79-79(1)
Authors: Hirano T.; Uchimura N.; Tsuchiyama Y.; Sakamoto T.; Hashizume Y.; Nakazawa Y.; Kotorii T.

Timed Melatonin Administration on Circadian Rhythms and Vigilance States
pp. 79-79(1)
Authors: Wirz-Justice A.; Cajochen C.; Krauchi K.; Mori D.; Graw P.

Sleep EEG and Nocturnal Hormone Secretion after Traumatic Brain Injury
pp. 79-79(1)
Authors: Steiger A.; Frieboes R.-M.; Murck H.; Holsboer F.; Muller U.; von Cramon D.Y.

Melatonin Secretion Exhibits Tolerance During Chronic Fluvoxamine Treatment in Medicated Schizophrenic Patients
pp. 79-79(1)
Authors: Silver H.; Barash I.; Odnopozov N.; Jahjahl N.

Serotonergic Control of Melatonin Secretion: The Role of 5HT-_1A Receptors
pp. 80-80(1)
Authors: Nathan P.J.; Norman T.R.; Burrows G.D.

The Assessment of PTSD in Veterans
pp. 80-80(1)
Author: Raphael B.

Biological Paradigms of the Attentional Processing in Post Traumatic Stress Disorder
pp. 80-80(1)
Authors: McFarlane A.C.; Clark R.; Weber D.; Galletly C.

Neuroendocrine Alterations in PTSD
pp. 80-80(1)
Author: Yehuda R.

Naloxone Reveals Decreased Threshold for Hypothalamic CRH Release in PTSD
pp. 80-80(1)
Authors: Jackson R.; Hockings G.; Grice J.; Ward W.; Walters M.; Jensen G.

The Modified Dexamethasone Suppression Test (mDST) in Chronic PTSD
pp. 80-81(2)
Authors: Hopwood M.; Marcina J.; Norman T.; Morris P.; Schweitzer I.

Central Noradrenergic and Serotonergic Neurotransmitter Function in Chronic PTSD
pp. 81-81(1)
Authors: Morris P.; Hopwood M.; Marcina J.; Norman T.; Schweitzer I.

Concentration/Effect Relationships in Clinical Psychopharmacology: Clinical Trials Designs
pp. 81-81(1)
Authors: Balant L.P.; Balant-Gorgia E.A.

Clinical Pharmacokinetic Update on Anticonvulsants
pp. 81-81(1)
Authors: Ketter T.A.; Frye M.A.; Callahan A.M.; Marangell L.B.; Post R.M.

Theoretical Considerations of Dose/Concentration/Effect Relationships: Direct and Indirect Pharmacokinetic/Dynamic Models
pp. 81-82(2)
Author: DeVane C.L.

Measurement of Lithium Brain Concentration by Li-7 MRS and Correlation with Effects
pp. 82-82(1)
Authors: Kato T.; Takahashi S.

Clinical Pharmacokinetics of Serotonin Reuptake Inhibitor and Newer Antipsychotic Drugs
pp. 82-82(1)
Author: Norman T.R.

Biological Predictors of Response
pp. 82-82(1)
Authors: Marazziti D.; Conti L.

Long Term Treatment of Panic Disorder-Agoraphobia
pp. 82-82(1)
Authors: Perugi G.; Musetti L.; Toni C.; Cassano G.B.

Predictors of Response in Obsessive-Compulsive Disorder
pp. 82-82(1)
Authors: Zohar J.; Sasson Y.; Cohen R.; Iancu I.; Dolberg O.

Temperament and Pharmacological Response in Depression
pp. 83-83(1)
Author: Akiskal H.S.

Clinical Predictions of Response to Treatments in Mood Disorders
pp. 83-83(1)
Author: Montgomery S.A.

Consequences of Corticosteroid Receptor Ablation
pp. 83-83(1)
Authors: Cole T.J.; Blendy J.A.; Monaghan A.P.; Krieglstein K.; Berger S.; Schmid W.; Unsicker K.; Schutz G.

Brain Corticosteroid Receptors and Stress System Disorders
pp. 83-83(1)
Author: de Kloet E.R.

Regeneration and Inactivation of Bioactive Corticosteroids: Windows for Neuro-Pharmaceutical Intervention
pp. 83-83(1)
Author: Krozowski Z.S.

Mineralocorticoid Receptor mRNA Variants in the Developing Hippocampus: Distribution and Regulation
pp. 84-84(1)
Authors: Vazquez D.M.; Kwak S.K.; Lopez J.F.; Watson S.J.; Akil H.

Intracerebral Antisense Oligonucleotides Reduce Mineralocorticoid-Induced Ingestive Behaviors
pp. 84-84(1)
Authors: Sakai R.R.; Ma L.Y.; Fluharty S.J.

Lithium Treatment in Psychiatry: Early Development and Recent Observations
pp. 84-84(1)
Author: Johnson G.

The Lithium Ion: A Foundation for Psychopharmacological Specificity
pp. 84-84(1)
Authors: Soares J.C.; Gershon S.

Rapid Cycling Bipolar Disorder: An Update
pp. 84-85(2)
Author: Dunner D.

Lithium in Comparison to Valproate and Carbamazepine
pp. 85-85(1)
Author: Bowden C.L.

Important Factors in Long-Term Maintenance Therapy
pp. 85-85(1)
Author: Kane J.M.

Medication Choices In Maintenance Antipsychotic Therapy: Theory and Clinical Practice
pp. 85-85(1)
Author: Remington G.

Long-Term Use of Novel Antipsychotics Side-Effects, Safety and the Risks of Non-Compliance
pp. 85-85(1)
Author: Keks N.A.

Clinical Experience Of Relapse Prevention with Novel Antipsychotics in Chronic Schizophrenia
pp. 85-86(2)
Author: Grebb J.

Aiding Resocialisation of the Complaint Chronic Psychotic Patient
pp. 86-86(1)
Author: Leff J.

The Serotonin Transporter: From Molecular Pharmacology to Therapeutics
pp. 86-86(1)
Authors: Langer S.Z.; Graham D.

Neuronal Transporters as Candidate Genes for Affective Disorders
pp. 86-86(1)
Authors: Lesch K.P.; Heils A.; Bengel D.; Teufel A.; Seemann M.; Petri S.; Goszler S.; Gross J.; Balling U.; Riederer P.; Stober G.

Clinical Onset of Antidepressant Action: Implications for New Drug Development
pp. 86-87(2)
Authors: Potter W.Z.; Manji H.K.

The Continuum of Affective Disorders In Women -- Diagnostic and Therapeutic Implications
pp. 87-87(1)
Author: Halbreich U.

CNS Roles of CRF and Urocortin, their Receptors and Binding Protein
pp. 87-87(1)
Authors: Vale W.; Vaughan J.; Donaldson C.; Perrin M.; Sutton S.; Bittencourt J.; Rivier J.; Sawchenko P.

Gender Differences in the Response to Pharmacotherapy among Early Onset Dysthymics
pp. 87-87(1)
Authors: Yonkers K.A.; Rush A.J.; Kornstein S.; Halbreich U.; Pearlstein T.; Stone A.

Mood Effects of Hormonal Interventions -- Comparisons to Conventional Antidepressants
pp. 87-88(2)
Authors: Freeman E.W.; Rickels K.; Sondheimer S.J.

Psychopharmacology of Pregnant and Postpartum Women
pp. 88-88(1)
Authors: Stowe Z.N.; Nemeroff C.B.

The Psychobiology of Female Specific Mood Disorders -- Discussion
pp. 88-88(1)
Authors: Steiner M.; Dunn E.

Platelet Immunoreactivity and Radioligand Binding to Imidazoline Receptors in Depression
pp. 88-88(1)
Authors: Halaris A.; Piletz J.; Ivanov T.; Zhu H.; Madakasira S.; Y. Z.F.; Goldman N.

Imidazoline Receptors: CNS Pharmacology and Clinical Relevance
pp. 88-88(1)
Authors: Nutt D.J.; Hudson A.; Husbands S.; Jackson H.C.; Lione L.; Lalies M.D.; Lewis J.; Reynolds G.

I1 and 12 Imidazoline Receptors in the Human Striatum: Comparison to Other Species
pp. 89-89(1)
Authors: Vauquelin G.; Flamez A.; Czerwiec E.; Vanderheyden P.; DeBacker J.P.

Agmatine and Other Endogenous Ligands at Imidazoline Receptors
pp. 89-89(1)
Authors: Reis D.J.; Regunathan S.

Distribution and Regulation of Imidazoline Receptors in the Brain
pp. 89-89(1)
Authors: Piletz J.; Ivanov T.; Zhu H.; Blackwell H.; Halaris A.

Youth Suicide in Victoria: A Retrospective Study
pp. 89-89(1)
Authors: Burrows G.D.; Tiller W.G.; Krupinski J.

Iatrogenesis and Medication as Potential Factors in Suicide and Depression
pp. 89-90(2)
Author: Gangat A.E.

Postmortem Brain and Platelet Receptor Changes in Suicide/Depression
pp. 90-90(1)
Author: Hrdina P.D.

G Proteins in the Postmortem Brain of Suicide Victims
pp. 90-90(1)
Authors: Pandey G.N.; Dwivedi Y.; Pandey S.C.; Goel S.; Conley R.; Roberts R.

Low Serum Cholesterol, Suicide and Serotonin
pp. 90-90(1)
Authors: Pitchot W.; Hild B.; Ansseau M.

Pharmacological Treatment of OCD: Are the Specific Serotonin Reuptake Inhibitors Superior to Clomipramine?
pp. 90-90(1)
Authors: Flament M.; Bisserbe J.C.; Boyer P.; Lecrubier Y.

Role of the Terminal 5-HT Autoreceptor in the Orbitofrontal Cortex in the Mechanism of Action of 5-HT Reuptake Inhibitors in Obsessive Compulsive Disorder
pp. 91-91(1)
Authors: Blier P.; El Mansari M.; Ducharme V.; Bouchard C.

New Insights to the Serotonin Hypothesis of OCD
pp. 91-91(1)
Authors: Zohar J.; Sasson Y.; Cohen R.; Kindler S.

Specific Brain Systems in Obsessive-Compulsive Disorder Treatment
pp. 91-91(1)
Authors: Baxter L.; Brody A.; Saxena S.; Schwartz J.; Ackermann R.

New Developments in Impulsivity and Compulsivity
pp. 91-91(1)
Author: Hollander E.

Dopamine Receptor Transcript Expression in Schizophrenia
pp. 92-92(1)
Authors: Meador-Woodruff J.H.; Damask S.P.; Haroutunian V.; Davidson M.; Powchik P.; Davis K.L.; Watson S.J.

Glutamatergic Abnormalities in the Temporal Lobe in Schizophrenia
pp. 92-92(1)
Author: Kerwin R.

Temporal Lobe Cytoarchitectural Pathology in Schizophrenia
pp. 92-92(1)
Author: Beckmann H.

Altered Gene Expression for Receptors and Transmitters in Prefrontal Cortex of Schizophrenics
pp. 92-92(1)
Author: Jones E.G.

The Neuropathology of Schizophrenia: Autoradiographic and In Situ Hybridization Studies
pp. 92-93(2)
Author: Kleinman J.E.

Metabolism, Kinetics and Interactions in Treating Refractory Depression
pp. 93-93(1)
Authors: Sellers E.M.; Romach M.K.

Treatment-Resistant Depression: Resistant and Complicated Depression
pp. 93-93(1)
Author: Price L.H.

Refractory Depression: First Line Treatment
pp. 93-93(1)
Author: Joffe R.

Treatment Refractory Depression: Long Term Issues
pp. 93-93(1)
Author: Keller M.B.

Implications of Comorbidity for the Treatment of Depression
pp. 93-94(2)
Authors: Burrows G.D.; Norman T.R.

Immediate Early Gene Expression and the Mechanisms of Action of Atypical Antipsychotics
pp. 94-94(1)
Author: Fibiger H.C.

Multiple Serotonin/Dopamine Receptor Interactions Contribute to Atypical Antipsychotic Drug Action
pp. 94-94(1)
Author: Meltzer H.Y.

Brain Biochemistry in the Normal and Hypoglutamatergic State -- What distinguishes Atypical from Typicial Antipsychotics? A Multivariate Approach
pp. 94-94(1)
Authors: Waters N.; Holm S.; Carlsson A.; Hansson L.O.

Stabilization of Brain DA Systems in Psychosis by Concomitant 5-HT₂ and ₂-Receptor Blockade
pp. 94-95(2)
Author: Svensson T.H.

Actions of Lithium on Brain Adenylyl Cyclase: Role of Magnesium
pp. 95-95(1)
Author: Mork A.

Marcks: A Key to the Long-Term Therapeutic Action of Mood Stabilizers in the Brain?
pp. 95-95(1)
Authors: Lenox R.H.; Watson D.G.; McNamara R.K.

Regulation of Transmembrane Signalling Systems by Mood Stabilizing Agents: Therapeutic Implications
pp. 95-95(1)
Author: Manji H.K.

The Inositol Depletion Hypothesis: Promise and Problems
pp. 95-96(2)
Author: Belmaker R.H.

Lithium Effects on Protein Phosphorylation in Bipolar and Healthy Subjects
pp. 96-96(1)
Authors: Zanardi R.; Racagni G.; Smeraldi E.; Perez J.

NGF, How it all Began and How Modern Technologies Confirm and Expand the Original Hypothesis
pp. 96-96(1)
Author: Shooter E.

Modulation of Activity-Dependent Neuronal Plasticity: A New Facet of Neurotrophin Action
pp. 96-96(1)
Author: Thoenen H.

Neurotrophic Factors: Biology & Clinical Potential
pp. 96-96(1)
Author: Lindsay R.M.

Opposing Effects of Stress and Antidepressants of Neurotrophic Factors
pp. 96-97(2)
Authors: Post R.M.; Smith M.; Weiss S.R.B.; Beaulieu S.; Chuang D.-M.

A Role for Neurotrophins in the Action of Chronic Antidepressant Treatments
pp. 97-97(1)
Author: Duman R.S.

Gender Differences in Health and Mental Health: Practical Implications
pp. 97-97(1)
Author: Nadelson C.C.

Estrogen in Postmenopausal Women with and without Depression: EEG, Endocrinological and Psychometric Studies
pp. 97-97(1)
Authors: Saletu B.; Halbreich U.

Gonadal Hormones, GABA and Benzodiazepine Receptors
pp. 97-97(1)
Authors: Weizman A.; Gavish M.

Estrogen and Thyroid Hormones as Adjuncts for Antidepressant Treatment of Post-Menopausal Women
pp. 97-98(2)
Author: Stahl S.M.

Pharmacotherapy of Depression in Women: Ethical, Conceptual and Practical Considerations
pp. 98-98(1)
Author: Halbreich U.

Adenosine Receptors as a Target for Carbamazepine's Action in the Brain
pp. 98-98(1)
Authors: Van Calker D.; Biber K.; Walden J.; Berger M.

Calciumantagonism as a Common Mode of Action of Some Antiepileptic Drugs in the Treatment of Epilepsies and Affective Disorders
pp. 98-98(1)
Authors: Walden J.; von Wegerer J.; Heszlinger B.; Berger M.

New Concepts in Mood Stabilization: Evidence for the Effectiveness of Valproate and Lamotrigine
pp. 98-98(1)
Author: Bowden C.L.

Lamotrigine in Treatment Refractory Manic Depression
pp. 98-99(2)
Author: Calabrese C.

Oxcarbazepine, Carbamazepine and Valproate in the Treatment of Affective and Disintegrative Psychiatric Disorders
pp. 99-99(1)
Authors: Emrich H.M.; Leweke M.; Schneider U.

Schizophrenia Spectrum Disorders: Electrophysiological and Structural MRI Features
pp. 99-99(1)
Authors: McCarley R.W.; Shenton M.E.; O'Donnell B.F.; Dickey C.C.; Holinger D.

Childhood Predictors of Schizotypal Features in Non-Psychotic Adults
pp. 99-99(1)
Authors: Cornblatt B.; Obuchowski M.; Erlenmeyer-Kimling L.

Neurobiology of the Schizophrenia Spectrum
pp. 99-99(1)
Authors: Siever L.J.; Buchsbaum M.; Cornblatt B.; Harvey P.; Bergman A.; Siegel B.; Hazlett E.; Callahan A.; New A.S.; Downhill J.

A Multidimensional Approach to Schizotypal Disorder
pp. 99-100(2)
Author: Battaglia M.

Hippocampal Volume Reduction and Cognitive Deficits: Course from High Risk to Chronic Schizophrenia
pp. 100-100(1)
Authors: Velahoulis D.; Brewer W.; McGorry P.; Paton G.; Yung A.; Francey S.; Pantelis C.

Hypnotic Use in a Psychiatric Department
pp. 100-100(1)
Authors: Onen S.H.; Jalenques I.; Coudert A.J.

Long-Term Use of Benzodiazepine Hypnotics
pp. 100-100(1)
Authors: Sugiyama T.; Takeuchi H.; Kobayashi K.; Isawa S.; Matsumoto C.; Ishigooka J.; Murasaki M.

Sleep Studies in Insomnia Based on Generalized Anxiety Disorder with Diphenhydramine/Lorazepam (Somnium^R)
pp. 100-101(2)
Authors: Zyhlarz G.; Saletu B.; Brandstatter N.; Frey R.; Anderer P.; Gruber G.; Klosch G.; Mandl M.; Stanger E.

The Effect of Trazodone on Sleep in Healthy Young Adults
pp. 101-101(1)
Authors: Kaneta K.; Hayasaka H.; Kawasaki M.; Ikemoto M.; Murakami S.; Takahata N.; Hatta S.

Effects of Zopiclone, Zolpidem and Flunitrazepam on Nocturnal Psychomotor and Cognitive Functions in Normal Young Subjects
pp. 101-101(1)
Authors: Patat A.; Le Coz F.; Thebault C.; Allain H.; Gandon J.M.

Effects of Zolpidem, Triazolam and Zopiclone on REM Sleep and Hippocampal Theta Activity in Rats
pp. 101-101(1)
Authors: Yoshimoto M.; Higuchi H.; Kamata M.; Yoshida K.; Takahashi H.; Ito K.; Shimizu T.; Hishikawa Y.

Sleep Endocrine Effects of Neuropeptide Y in Men Reveal a GABA_A-Agonistic Action
pp. 101-101(1)
Authors: Steiger A.; Antonijevic I.A.; Bohlhalter S.; Murck H.; Frieboes R.-M.; Schier T.; Holsboer F.

Clinical and Chronobiological Effects of Sleep Deprivation on Depressed Patients
pp. 102-102(1)
Authors: Yamada N.; Ohi K.; Nakajima S.

Linkage Study of Narcolepsy in 7 Japanese Families
pp. 102-102(1)
Authors: Himei A.; Yoneda H.; Inayama Y.; Sakai J.; Sakai T.; Miki T.; Honda Y.

Acute Nocturnal Doses of Short-Acting Benzodiazepines Suppress Melatonin Secretion in Humans
pp. 102-102(1)
Authors: McNulty O.; Norman T.R.; Nathan P.J.

The Relationship Between Serotonin and Melatonin in the Rat Pineal Gland
pp. 102-102(1)
Authors: Nathan P.J.; Norman T.R.; Burrows G.D.

Changes in Circadian Rhythm of Activity in Depression Model Depend on Dark/Light Phase of Test Start
pp. 102-103(2)
Authors: Gaztelu J.M.; Montes J.M.; Barrenechea C.; Romero M.; Saiz-Ruiz J.

Effects of Vitamin B₁₂ on the Lithium Carbonate-Induced Prolongation of Free-Running Period in Rat Circadian Rhythms
pp. 103-103(1)
Authors: Tsujimaru S.; Ida Y.; Fukuyama H.

Circadian Variation in the Ambulatory and Drinking Activities After Repeated Administration of Cocaine in Rats
pp. 103-103(1)
Authors: Asami T.; Shinoda M.; Kuribara H.; Ida I.; Mikuni M.; Machiyama Y.; Yukio I.

The Role of Dopamine System in the Striatum on the Light Pulse Induced PRCS
pp. 103-103(1)
Authors: Fukuyama H.; Tsujimaru S.; Ida Y.

Differing Properties of Dopamine Agonists and Partial Agonists at the Cloned Human D₂₁ and D_4.4 Receptors
pp. 103-103(1)
Authors: Lahti R.A.; Mutin A.; Cochrane E.; Dijkstra D.; Wikstrom H.; Lahti A.C.; Tamminga C.A.

Fos-like Immunoreactivity in the Rat Brain Induced by Clozapine, Risperidone, Haloperidol, and Haloperidol Combined with Antidepressant.
pp. 104-104(1)
Authors: Kwang-Soo K.; Won-Myong B.; Yang-Whan J.

Similar Effects of Chronic Clozapine and 'Seroquel' (ICI 204,636) Administration on ₁FosB Expression in the Forebrain
pp. 104-104(1)
Authors: Ansari F.; Nakabeppu Y.; Robertson G.S.

Effect of YM-43611 and Neuroleptics on c fos Expression in the Rat Forebrain
pp. 104-104(1)
Authors: Narita M.; Kurokawa K.; Koshiya K.; Hidaka K.; Ohmori J.; Satoh K.

Receptor Mechanisms Mediating Clozapine-Induced c-fos Expression
pp. 104-104(1)
Author: Fibiger H.C.

Differential Roles of D2, D3 and D4 Receptors in Dopamine-Related Behaviors as Assessed With a Novel D3D4 Antagonist YM-43611
pp. 104-105(2)
Authors: Koshiya K.; Nakatoh K.; Hattori H.; Usuda S.

Dopamine D2 Receptor Change After Repeated Treatment with SM-9018, a Novel Neuroleptic
pp. 105-105(1)
Authors: Ohno Y.; Ishibashi T.; Ikeda K.; Ishida K.; Nakamura M.

Is Clozapine a Dopaminergic Drug?
pp. 105-105(1)
Authors: S. W.T.; Helmeste D.M.; Fang H.; M. L.; Widmark C.; Reist C.

Comparison of the Pharmacological Profiles of Zotepine and Norzotepine
pp. 105-105(1)
Authors: Heal D.J.; Needham P.L.

BTS 73 947, A Novel D1/D5 Antagonist with Predicted Atypical Antipsychotic Activity
pp. 105-105(1)
Authors: Needham P.L.; Heal D.J.; Sargent B.J.; Buckett W.R.

Behavioral Studies of OPC-14597, a Novel Antipsychotic Drug
pp. 106-106(1)
Authors: Kikuchi T.; Uwahodo Y.; Tottori K.; Nakai M.; Hirose T.; Oshiro Y.; Morita S.

Pharmacological Profile of PR-000608, a Novel Dopamine Uptake Inhibitor
pp. 106-106(1)
Authors: Inazu M.; Harada M.; Kubota N.; Masuda T.

The Effects of Clozapine and Remoxipride on Latent Inhibition in Rats
pp. 106-106(1)
Authors: Trimble K.M.; King D.J.; Bell W.R.

'Seroquel' (ICI 204,636) and Clozapine are Effective in an Animal Model of the Negative Symptoms of Schizophrenia
pp. 106-106(1)
Authors: Ellenbroek B.; Lubbers L.; Cools A.

Clozapine-Like Behavioral Effects of 'Seroquel' (ICI 204,636) in Squirrel Monkeys
pp. 106-107(2)
Authors: Carey G.; Bergman J.

Pharmacology of 'Seroquel' (ICI 204,636): An Atypical Dibenzothiazepine Antipsychotic
pp. 107-107(1)
Author: Goldstein J.M.

Response of Animal Model for Tardive Dyskinesia to Central Drugs
pp. 107-107(1)
Authors: Takeuchi H.; Kato Y.; Yago K.; Watanabe S.; Ishigooka J.; Murasaki M.; Miura S.

Seroquel Restores Prepulse Inhibition of Startle in Phencyclidine-Treated Rats
pp. 107-107(1)
Authors: Swerdlow N.; Bakshi V.; Geyer M.

Phencyclidine-Induced Schizophrenia Negative Symptom-Like Behavior in Mice: Comparative Study of Risperidone and Haloperidol
pp. 107-107(1)
Authors: Noda Y.; Yamada K.; Nabeshima T.

Effects of Developmental Phencyclidine Exposure on Auditory Startle and Locomotor Activity
pp. 108-108(1)
Author: Scalzo F.M.

Effect of Dantrolene on Caffeine-Induced Dopamine Release in Rat Striatum
pp. 108-108(1)
Authors: Oyamada T.; Hayashi T.; Kagaya A.; Yokota N.; Yamawaki S.

Lipoxygenase Pathway Modulation of Dopamine Release
pp. 108-108(1)
Authors: Davidson B.; Giangregorio A.; Lambert L.; Van Blerk D.

Effect of Glutamate Uptake Inhibitor L-trans-PDC on Amino Acids in Rat Striatum: Microdialysis Study
pp. 108-108(1)
Authors: Semba J.; Sakai M.; Kito S.

Dopaminergic Modulation of GABA Release: In Vivo Microdialysis in Freely Moving Rats
pp. 108-108(1)
Authors: Javaid J.; Shim I.; Wirtshafter D.

Changes of Monoamine Synapses and Behavior in Rats Induced by Fetal Injection of Methylazoxymethanol
pp. 109-109(1)
Authors: Watanabe M.; Kodama Y.; Kimura K.; Takishima K.; Mamiya G.; Ichinowatari N.

The Peculiarities of the Meperedine Action in Early Ontogenesis
pp. 109-109(1)
Authors: Zlenko H.; Demechenko H.

Inhibitory Role of Brain Histaminergic Neuron System on Behavioral Sensitization
pp. 109-109(1)
Authors: Ito C.; Onodera K.; Watanabe T.; Sato M.

Gonadal Hormones and the Presynaptic Transporters for Dopamine and Serotonin in Rat Brain
pp. 109-109(1)
Authors: Attali G.; Gil-Ad I.; Weizman R.; Rehavi M.

Activation of Noradrenergic Neurons in the Rat Locus Coeruleus and Noradrenaline Release in the Amygdala
pp. 109-110(2)
Authors: Tanaka M.; Ishii H.; Nishikawa T.; Yoshida M.; Yokoo H.; Tanaka T.

Anti-₂-GP and Anti-GFAP Antibodies as the Vectors for Targeted Delivery of Haloperidol into the Glial Cells
pp. 110-110(1)
Authors: Chekhonin V.; Kabanov A.; Rjabukhin I.; Antonova O.; Belaeva I.; Khrustaleva N.; Anin A.; Alexandrovsky Y.; Dmitrieva T.

Platelet Paroxetine Binding in Post-traumatic Stress Disorder
pp. 110-110(1)
Authors: Maguire K.; Norman T.; Hopwood M.; Morris P.

Experimental Study: Stress and Memory
pp. 110-110(1)
Authors: Le Poncin M.; Lamproglou I.

Interaction of Glucocorticoid Receptor with Heat Shock Protein 90 after Chronic Stress
pp. 110-110(1)
Authors: Sasuga Y.; Asakura M.; Miyamoto M.; Bodaiji N.; Imafuku J.; Matsushita T.; Aoba A.

Effect of Dilithium N-Acetyl-L-Aspartate on Stress-Induced Dopamine Release in Hypothalamus
pp. 111-111(1)
Authors: Petrov V.; Grigoryev I.; Zaretsky D.; Sergeyev V.

Stress-Induced Phase-Shifts in the Locomotor Activity Rhythm and Increases in Noradrenaline Turnover in the Locus Coeruleus Region
pp. 111-111(1)
Authors: Tsujimaru S.; Ida Y.; Egami H.

The Effect of Prenatal Stress on the Development of the Rat Aminergic Receptors and Behavior
pp. 111-111(1)
Authors: Asou T.; Yoshimoto S.; Tsujimura T.; Tomimatsu Y.; Kakumoto Y.; Okazaki Y.; Nakane Y.

Effects of Acute and Chronic Administration of CCKB Antagonist on Conditioned Fear Stress
pp. 111-111(1)
Authors: Izumi T.; Inoue T.; Tsuchiya K.; Hashimoto S.; Ohmori T.; Koyama T.

Pharmacological Regulation of Anxiety in Dependence on Stress Reaction Phenotype
pp. 111-111(1)
Author: Seredenim S.B.

Comorbidity and Treatment Features in Social Phobia
pp. 111-112(2)
Author: Nardi A.E.

Sertraline in Obsessive-Compulsive Spectrum Disorders -- A Case Study Series
pp. 112-112(1)
Authors: Bisserbe J.C.; Lane R.

Effect Size, Placebo Response and Tolerability in Clinical Studies in Obsessive-Compulsive Disorder
pp. 112-112(1)
Authors: Bisserbe J.C.; Lane R.

Generalized Anxiety (GA) and Panic Attacks (PA): The Pathogenic Targets for Psychopharmacology
pp. 112-112(1)
Authors: Avedisova A.; Kogan B.; Paniushkina S.; Darovsky N.

Two-Year Follow-Up After Treatment of Panic Disorder with Agoraphobia
pp. 112-112(1)
Authors: van Balkom A.J.L.M.; de Beurs E.; van Dyck R.; Lange A.

Double-Blind Comparison of Sertraline and Placebo in Patients with Panic Disorder
pp. 112-113(2)
Authors: Baumel B.; Bielski R.; Carman J.; Goodman W.; Hegel M.; Houck C.; Linden R.; Nakra B.; Ota K.; Rohl R.; Wolkow R.

Can Panic Disorder Patients Treated With More Than 4 mg/day of Alprazolam Reduce Their Dose?
pp. 113-113(1)
Authors: Corrigan M.; Jonas J.; Kitt t.; Goldstein S.; Swiontek A.; Stahl S.

Efficacy and Safety of Paroxetine in Panic Disorder
pp. 113-113(1)
Author: Judge R.

Double-Blind Flexible Dose Study of Sertraline and Placebo in Patients with Panic Disorder
pp. 113-113(1)
Authors: Wolkow R.; Apter J.; Clayton A.; Coryell W.; Cunningham L.; McEntee W.; O'Hair D.; Pollack M.; Rausch J.; Stewart R.; Weisler R.

CCK-4 in Cerebrospinal Fluid: A Pilot Study in Healthy Male Volunteers
pp. 113-113(1)
Authors: Gunnarsson T.; Eklundh T.; Eriksson M.; Nordin C.; Sjoberg S.

Effect of a Major Depressive Episode History on the CCK-4 Response in Women
pp. 113-114(2)
Authors: Le Melledo J.-M.; Bradwejn J.; Koszycki D.; Bellavance F.; Bichet D.G.

The Role of the Beta Adrenergic System in CCK-4 Induced Panic Symptoms
pp. 114-114(1)
Authors: Le Melledo J.-M.; Bradwejn J.; Koszycki D.; Jerabek I.; Jolicoeur F.; Cadieux A.; Boulenger J.-P.; Bellavance F.; Bichet D.G.

Mutation in the Cholecystokinin B Receptor in Panic Disorder
pp. 114-114(1)
Authors: Miyamoto M.; Isogawa K.; Akiyoshi J.

CCK-4-Induced Calcium Mobilization in T Cells is Enhanced in Panic Disorder
pp. 114-114(1)
Authors: Akiyoshi J.; Moriyama T.; Isogawa K.; Miyamoto M.; Sasaki I.; Kuga K.; Yamamoto H.; Yamada K.; Fujii I.

Effect of Provoking Panic Attack Agents on Extracellular Level of 5-Hydroxytryptamine in Hippocampus of Free Moving Rats
pp. 114-114(1)
Authors: Isogawa K.; Miyamoto M.; Akiyoshi J.

Anxiolytic Activity of GV 150013, a New Potent and Selective Cholecystokinin-B (CCK-B) Antagonist
pp. 114-115(2)
Authors: Trist D.G.; Corsi M.; van Amsterdam F.T.M.; Ratti E.; Gaviraghi G.; Reggiani A.

An Association Study Between Panic Disorder and Serotonin 2C Receptor DNA Marker
pp. 115-115(1)
Authors: Inada Y.; Yoneda H.; Inayama Y.; Nonomura Y.; Kuroda K.; Asaba H.; Sakai T.

5-HT2C Receptor Antagonists and Anxiety Disorders
pp. 115-115(1)
Authors: Blackburn T.P.; Lightowler S.; Kennett G.A.; Wood M.D.; Middlemiss D.N.

Anxiolytic Effects of Y-23684 in Normal Humans with High-and Low-Anxiety
pp. 115-115(1)
Authors: Mizuki Y.; Suetsugi M.; Yamada M.

Anticonvulsant and Anxiolytic Effects of LY300164, an Orally Effective AMPA Antagonist
pp. 115-115(1)
Author: Leander J.D.

Benzodiazepine-Mediated Overactivation of 5-HT2 Behavioural Responses in Rodents
pp. 115-116(2)
Authors: Leonsegui I.; Salvador-Carulla L.

Benzodiazepine-Serotonin Receptor Interactions: Studies in Animal Behavioural Models
pp. 116-116(1)
Authors: Norman T.R.; Beveridge A.; Sedman G.

Activity of 5HT-3 Receptor Active Compounds in Animal Behavioural Models of Anxiety
pp. 116-116(1)
Authors: Sedman G.; Becker P.L.; Norman T.R.

The Effects of the CCK Antagonist, Proglumide, on Latent Inhibition in Rats
pp. 116-116(1)
Authors: Gracey D.J.; Bell W.R.; King D.J.

AP521, A Novel Benzothieno-Pyridine Derivative, Shows Anxiolytic Activity
pp. 116-116(1)
Author: Nagatani T.

Bimodal Effects of GABAergic Drug Penicillin on Anxiety
pp. 116-117(2)
Author: Kalueff A.V.

Modulation of Grooming Behaviour by GABAergic Drug Penicillin
pp. 117-117(1)
Author: Kalueff A.V.

New Day Tranquilizer -- Tarden
pp. 117-117(1)
Authors: Denisenko P.P.; Pukhov M.P.; Denisenko N.P.; Tarasenko A.A.; Abyshev A.Z.

Anxiolytic Effects of Ziprasidone Compared with Diazepam and Placebo Prior to Dental Surgery
pp. 117-117(1)
Authors: Wilner K.D.; Anziano R.J.; Johnson A.C.; Miceli J.J.; Fricke J.R.; Titus C.K.

Anxiety-Depressive Disorders after Subarachnoid Hemorrhage (SAH): Association With Fatiguability
pp. 117-117(1)
Authors: Starmark J.E.; Rodholm M.; Svensson E.; von Essen C.

Gender Differences in Body Temperature During Lorazepam Tolerance and Withdrawal
pp. 118-118(1)
Authors: Elliot E.; White J.

Withdrawal of Lorazepam Long-Term Administered Using Six Different Plans
pp. 118-118(1)
Authors: Lemoine P.; Touchon J.; Billardon M.

Mechanistic Studies with Addictive Sedative-Hypnotics and Related Drugs in the Mouse
pp. 118-118(1)
Authors: Shulman A.; Laycock G.; Han G.

An Animal Model of Benzodiazepine Withdrawal: The Effect of 5HT-IC Receptor Active Compounds
pp. 118-118(1)
Authors: Sedman G.; Dwyer L.; Norman T.R.

Relationship between Diazepam Withdrawal Signs and GABA Receptor Function in Rats
pp. 118-119(2)
Authors: Toki S.; Nabeshima A.; Saito T.; Watanabe M.; Takahata N.; Hatta S.

Cognitive Performance and Mood Changes over 24 Hours of Smoking Abstinence
pp. 119-119(1)
Authors: Parrott A.C.; Garnham N.; Wesnes K.

The Effects of Nicotine on the Color Word Test
pp. 119-119(1)
Authors: Nishimoto M.; Miyasato K.; Ohashi Y.; Kosuge K.; Ohashi K.; Ohara K.; Nakashima M.; Maruyama Y.

Central Nervous System Distribution of c-fos Expression in a Rat Model of Nicotine Craving
pp. 119-119(1)
Authors: Pich E.M.; Talabot D.; Pagliusi S.; Tessari M.; Chiamulera C.

Neural Mechanisms of Dependence on and Psychotoxicity of Nicotine and Stimulants
pp. 119-119(1)
Authors: Yanagita T.; Ando K.; Shimada A.

Carbamazepine-Mianserin in Opiate Withdrawal Study: A Double Blind Study Versus Clonidine
pp. 119-119(1)
Authors: Bertschy G.; Bryois C.; Bondolfi G.; Velardi A.; Baettig D.; Baumann P.

Alternative Pharmacotherapies in the Treatment of Opioid Addiction
pp. 120-120(1)
Authors: Broadbear J.H.; Lewis J.W.; Woods J.H.

Methadone Plasma Levels in a Methadone Maintenance Treatment
pp. 120-120(1)
Authors: Torrens M.; Castillo C.; San L.; del Moral E.; de la Torre R.

The mRNA Expression of G Protein Subclasses in the Methamphetamine-Induced Behavioral Sensitization
pp. 120-120(1)
Authors: Iwasa H.; Kikuchi S.; Suzuki K.; Sato T.; Hasegawa S.

Dopaminergic Modulation of Hypothalamic Self-Stimulation of Socially Isolated Rats with Lesions of Brain Mesolimbic Structures
pp. 120-120(1)
Authors: Shabanov P.D.; Panchenko G.N.; Lebedev A.A.

Induction of Immediate Early Genes Following Rewarding Brain Stimulation
pp. 120-120(1)
Authors: Hunt G.E.; McGregor I.S.

Flupenthixol and Desipramine Treatment of Crack Users: Double Blind Results
pp. 120-121(2)
Authors: Gawin F.H.; Khalsa-Denison M.E.; Jatlow P.

Incidence of Drug Dependency in Employees with Term Sick Leave in the Minicipality of Trollhattan
pp. 121-121(1)
Authors: Fagemo I.; Carlsson I.; Persson P.; Bjorling G.

Minimum Effective Doses of SSRIs
pp. 121-121(1)
Authors: Magnus R.; Preskorn S.; Lane R.

The SSRI Withdrawal Syndrome
pp. 121-121(1)
Authors: Preskorn S.; Lane R.; Magnus R.

Effects of the SSRIS on Cognitive Function
pp. 121-122(2)
Authors: Richter E.; Oxman T.; Lane R.

Predictors of Response to SSRIs in Patients with Major Depression
pp. 122-122(1)
Authors: Bisserbe J.C.; Lane R.; Wiseman R.

Clinical Experience with Paroxetine: A Review
pp. 122-122(1)
Author: Judge R.

A Double-Blind Multicentre Comparison of Paroxetene and Amitriptyline in Australian General Practice
pp. 122-122(1)
Authors: Freed E.; George T.; Goldney R.; Lambert T.; Tiller J.

Antidepressant Effects of Paroxetine in Korean Patients with Major Depression
pp. 122-123(2)
Authors: H. S.L.; S. K.M.; C. H.K.; D. H.S.; K. N.; W. T.J.

A Review of the Psychomotor Effects of Paroxetine
pp. 123-123(1)
Authors: Hawley C.J.; McPhee S.A.; Smith V.R.H.; Roberts A.G.

Cross-over Study of Sertraline Versus Imipramine in Chronic Depression
pp. 123-123(1)
Author: Keller M.

Sertraline Versus Imipramine in the Acute and Continuation Treatment of Dysthymia
pp. 123-123(1)
Author: Kocsis J.

Treatment of Severe Major Depression: A Double-Blind Study of Sertraline and Clomipramine
pp. 123-124(2)
Authors: Lepine J.; Wiseman R.

The Efficacy of Sertraline in the Treatment of Major Depression
pp. 124-124(1)
Authors: Bugarski-Kirola D.; Damjanovic A.; Paunovic V.R.; Zivkovic D.; Stankovic Z.

Sertraline in Continuation Therapy
pp. 124-124(1)
Authors: Montgomery S.; Lane R.

Sexual Side Effects during Sertraline Treatment of Patients with Mayor Depression: A Naturalistic Study
pp. 124-124(1)
Author: Varela A.L.

A Six Month Comparison of Toleration and Efficacy of Sertraline and Fluoxetine Treatment of Major Depression
pp. 124-124(1)
Authors: Latimer P.R.; Ravindran A.V.; Bernatchez J.-P.; Fournier J.-P.; Gojer J.A.; Barratt K.; Buttars J.

A Double Blind Comparison of Sertraline and Fluoxetine in the Treatment of Major Depressive Episode in Out Patient
pp. 124-125(2)
Authors: Rioux P.; Sechter D.; Troy S.

Psychotropic Comedication and Adverse Event Rates. Results from a Fluoxetine Drug Surveillance Study
pp. 125-125(1)
Authors: Dittmann R.W.; Linden M.; Osterheider M.

Serotonergic (Fluoxetine) Versus Noradrenergic (Maprotiline) Antidepressants and Suicidality
pp. 125-125(1)
Authors: Henigsberg N.; Jakovljevic M.; Vujic D.

Outcomes Including Withdrawal Phenomena Detected from a Naturalistic Comparison of Fluoxetine and Paroxetine Used in the Treatment of Affective Disorders in Patients with Learning Disabilities
pp. 125-125(1)
Authors: Bhaumik S.; Wildgust H.J.

Preliminary Results of a Randomized Double Blind Study of Amisulpride Vs Fluoxetine in 281 Dysthymic Patients
pp. 126-126(1)
Authors: Biondi F.; Casadei G.

Efficacy and Tolerability of Fluoxetine Compared with Maprotiline in Major Depressive Episode: Results of Central-East European Study
pp. 126-126(1)
Authors: Jakovljevic M.; Vujic D.; Aleksandrovsky Y.; Szerenberger W.; Faltus F.; Henigsberg N.

Fluvoxamine Alone in the Treatment of Delusional Depression
pp. 126-126(1)
Authors: Zanardi R.; Perez J.; Smeraldi E.

Effectiveness of Fluvoxamine Therapy in Cardiological Patients Suffering from Depression
pp. 126-126(1)
Authors: Radics J.; Mezes P.; Ostorharics G.

Fluvoxamine and Lithium in Long-Term Treatment of Unipolar Subjects
pp. 126-126(1)
Authors: Zanardi R.; Franchini L.; Perez J.; Smeraldi E.

Dexamethasone Augmentation of Sertraline Response in Resistant Depression
pp. 126-127(2)
Authors: Berti C.; Dinan T.; Cooney J.; Lavelle E.

Buspiron Augmentation of SSRI Therapy in Treatment-Refractory Depression
pp. 127-127(1)
Authors: Fahlen T.; &unknown;9gren H.; Edstrom A.; Rooth K.

Safety -> Tolerability of Combined Treatment with Moclobemide and SSRIs: A Preliminary Study
pp. 127-127(1)
Authors: Hawley C.J.; Ratnam S.; Quick S.; Echlin D.; Pattinson H.

Use of Combined SSRIS and Moclobemide in Treatment-Resistant Depression
pp. 127-127(1)
Author: Grounds D.

A Protocol for the Pharmacologic Treatment of Major Depression
pp. 127-127(1)
Authors: Hawley C.J.; Pattinson H.A.; Quick S.J.; McPhee S.A.

Compliance to Psychopharmacological Treatment: Suggestions for its Improvement
pp. 127-128(2)
Authors: Mantonakis J.; Christodoulou G.N.

Temperament, Character, and Molecular Genotypes as Predictors of Antidepressant Response
pp. 128-128(1)
Authors: Nicolini H.; Herrera K.; Paez F.; Camarena B.; Guajardo R.; De la Fuente J.R.

Polypharmacy: What is its Role in the Long-Term Use of Antidepressants?
pp. 128-128(1)
Author: Preskorn S.H.

Economic Impact of Improved Work Performance after Treatment of Chronic Depression
pp. 128-128(1)
Authors: Russell J.M.; Finkelstein S.N.; Berndt E.R.; Greenberg P.E.

Utility-Based Measures of Health-Related Quality of Life in Depression
pp. 128-128(1)
Authors: Bennett K.J.; Torrance G.W.; Boyle M.H.; Guscott R.

Dexamethasone Suppression Test in Depression
pp. 128-129(2)
Authors: Zivkovic-Milovanovic D.; Bugarski-Kirola D.; Stankovic Z.; Damjanovic A.

5-HT2A Receptor Gene is Intact in Mood Disorder
pp. 129-129(1)
Authors: Ohara K.; H. Y.Z.; Ishigaki T.; D. W.X.; Tani K.; Miyasato K.; Ohara K.

Anticipation and Repetitive Elements of the Serotonin Transporter Gene in Affective Disorder
pp. 129-129(1)
Authors: Hayashida M.; Tsujita T.; Imamura A.; Okazaki Y.; Niikawa N.; Nakane Y.; Matsumoto S.

Platelet Serotonin2 Receptor Binding in Affective Disorders
pp. 129-129(1)
Authors: Tsujimura T.; Asou T.; Hayashida M.; Himeno A.; Minami H.; Okazaki Y.; Nakane Y.

Strong and Long-Lasting Inhibition of 5-HT Uptake of Platelets in Subjects Treated by Duloxetine, an Antidepressant Candidate
pp. 129-129(1)
Authors: Kasahara T.; Nagata E.; Takahashi A.; Ishigooka J.; Murasaki M.; Miura S.

Tryptophan Depletion in Recovered Depressives and Recovered Bulimics
pp. 129-130(2)
Authors: Smith K.A.; Fairburn C.G.; Cowen P.J.

Therapeutic Advantage of Combined Amitriptyline/Lithium and Fluvoxamine/Lithium Treatments
pp. 130-130(1)
Authors: Miljkovic B.; Pokrajac M.; Timotijevic I.

Saccadic Eye Movements in Gilles-de-la-Tourette-Syndrome
pp. 130-130(1)
Authors: Muller N.; Riedel M.; Mennicken J.B.; Eggert T.; Straube A.

In Vivo Examination of the Pre- and Postsynaptic Dopamine Neurons in Huntington's Disease
pp. 130-130(1)
Authors: Ginovart N.; Lundin A.; Farde L.; Halldin C.; Swahn C.G.; Pauli S.; Sedvall G.

The Effects of Cues on Executive Functions of Parkinsonian Patients
pp. 130-131(2)
Authors: C. T.T.; C. H.J.; C. K.L.; R. T.L.; C. L.L.

Tolcapone Therapy Improves Cognitive Functions in Nondemented Patients with Advanced Parkinson's Disease
pp. 131-131(1)
Authors: Meco G.; Gasparini M.; Di Fabio R.; Vanacore N.; Bonifati V.

Acute Administration of Levodopa + Carbidopa Before and After Four Months of Treatment with Tolcapone in Advanced Parkinson's Disease
pp. 131-131(1)
Authors: Meco G.; Zuchegna P.; Fabrizio E.; Vanacore N.

Risperidone in Levodopa Induced Psychosis in Advanced Parkinson's Disease. An Open Label, Long-Term Study
pp. 131-131(1)
Authors: Meco G.; Alessandri A.; Giustini P.; Bonifati V.

Parkinsonism, Negative Symptomatology and Subjective Patient's Experience
pp. 131-131(1)
Authors: Marchesi G.F.; Santone G.; Cotani P.; Giuliani S.; Delicati F.; Chelli F.

A Fifteen Year Follow-Up Study of Tardive Dyskinesia and Drug Induced Parkinsonism
pp. 131-132(2)
Authors: Gardos G.; Casey D.E.; Perenyi A.; Cole J.O.; Kocsis E.; Samson J.A.; Wycoff W.

Effects of OPC-14117 on Dopaminergic Neuronal Degeneration Induced by MPTP
pp. 132-132(1)
Authors: Uwahodo Y.; Tottori K.; Kikuchi T.; Nakai M.; Miwa T.; Hirose T.; Oshiro Y.; Morita S.

Awareness of Tardive Dyskinesia and its Relationship to Tardive Dysmentia
pp. 132-132(1)
Author: Marsalek M.

Cognitive Impairment and Tardive Dyskinesia
pp. 132-132(1)
Authors: Shriqui C.L.; Annable L.; Doucet C.

Long-Term Treatment-Emergent Dyskinetic Symptoms in Patients Treated with Olanzapine and Haloperidol
pp. 132-132(1)
Authors: Street J.; Tamura R.; Sanger T.; Tollefson G.

Ratio of Neuroleptic to Anticholinergic Level and Extrapyramidal Symptoms Induced by Nemonapride
pp. 132-133(2)
Authors: Yamaguchi N.; Kamimura M.; Morokawa Y.; Fujimaki H.; Watanabe H.; Nagatsu Y.; Aoba A.

Akathisia, Iron and Cortisol
pp. 133-133(1)
Author: Houchin J.

Irritability Rating Scale: Validity and Reliability
pp. 133-133(1)
Authors: Thienhaus O.J.; Collins J.

Continuous Infusion of Haloperidol and Delerium in Intensive Care Unit
pp. 133-133(1)
Authors: Ait-ameur A.; Doise J.M.; Leuret-Barondeau A.; Piroth L.; Aube H.; Blettery B.; Gisselmann A.

Blue Notes (On Physicians Noncompliance)
pp. 133-133(1)
Author: Ramseier F.

Analgetic Properties of some Prolin-Containing Oligopeptides, having Antiulcer Effect
pp. 133-133(1)
Authors: Kopylova G.N.; Mamedov C.V.; Samonina G.E.

Ketamine: Neurophysiological Study of Subanesthetic Doses in Patients with Chronic Pain
pp. 134-134(1)
Authors: Oga K.; Matsuura M.; Nagashima M.; Kojima T.; Kato J.; Ogawa S.

The Influense of Ketamine Pharmacokinetics on the Activity of Neurotransmitter Systems in Humans under Surgical Stress
pp. 134-134(1)
Authors: Davydova N.A.; Tigranian R.A.; Borovkova T.F.; Abackumov M.M.; Gillis B.G.

Functional State of the System DOPHA-Dophamini (DA)-Noradrenalini (NA)-Adremalini (A) Under Epilepsy
pp. 134-134(1)
Authors: Karlov V.A.; Gleyzer M.A.; Sorokina N.D.

Psychiatric Morbidity in Candidates for Normal Volunteer Trials
pp. 134-134(1)
Authors: Gentil V.; Gorenstein C.; Andrade L.

Olanzapine Use after Clozapine Induced Granulocytopenia
pp. 135-135(1)
Authors: Swartz J.R.; Ananth J.; Smith M.; Burgoyne K.; Gadasally R.

Eight-Week Administration of Antipsychotic Drugs Decreases the Sensitivity of Vasopressin Secretion
pp. 135-135(1)
Authors: Kishimoto T.; Kitera K.; Shimayoshi N.; Noriyama Y.; Inoue Y.; Higashiura N.; Matsumoto H.; Nakagawa K.; Ohsawa H.

Duration of Initially Untreated Psychosis, Negative Symptoms and Cognitive Impairment in Schizophrenia
pp. 135-135(1)
Authors: Scully P.J.; Coakley G.; Youssef H.A.; Kinsella A.; Waddington J.L.

A Case-Control Study of Neuroleptic Malignant Syndrome
pp. 135-135(1)
Authors: Sachdev P.; Mason C.; Hadzi-Pavlovic D.

Antibodies to Human Heat, Shock Protein in Patients with Schizophrenia and Major Depression
pp. 135-135(1)
Authors: Sirota P.; Novogrotsky A.; Mazeh D.

Specific Cognitive Deficits in Schizophrenia
pp. 135-136(2)
Authors: Large M.; O'Sullivan B.; Smith G.; Kavanagh D.; Barrett N.; Karayanidis F.; Michie P.

Positive Association between Dopamine D4 Receptor Polymorphism and Schizophrenia
pp. 136-136(1)
Authors: Nakamura M.; Suzuki J.

The Effect of Neuroleptic Drugs on Olfactory Sensitivity in Schizophrenia
pp. 136-136(1)
Authors: Sirota P.; Ben-David I.; Luca-Haimovici K.; Zohar J.; Gross-Isseroff R.

Haloperidol-Induced NGF Plasma Levels Changes in Schizophrenic Patients
pp. 136-136(1)
Authors: Aloe L.; Bersani G.; Iannitelli A.; Maselli P.; Garavini A.; Angelucci F.; Alleva E.; Pancheri P.

Olfactory and Neuropsychological Deficits in High-Risk & First Episode Psychosis
pp. 136-136(1)
Authors: Brewer W.; Francey S.; Yung A.; Velakoulis D.; Anderson V.; McGorry P.; Copolov D.; Singh B.; Pantelis C.

Nightmares: Their Relationships with Mental Disorders and Sleep Disorders
pp. 136-137(2)
Authors: Ohayon M.M.; Priest R.G.; Guilleminault C.; Caulet M.

Effects of Ethyl Loflazepate on Nocturnal Sleep and Sleep Spindle in Normal Humans
pp. 137-137(1)
Authors: Suetsugi M.; Mizuki Y.; Yamada M.

Relationship between Sleep Disturbance and Pain in Patients with Fibromyalgia and Concomitant Treatment with the 5-HT2-Receptor Antagonist Ketanserine
pp. 137-137(1)
Authors: Hemmeter U.; Kocher R.; Hatzinger M.; Seifritz E.; Bischof R.; Lauer C.J.; Holsboer-Trachsler E.

Delta-Hypohypnia: A New Mechanism for Chronic Intractable Insomnia?
pp. 137-137(1)
Author: Char-nie C.

Sleep and Waking in 5,7-DHT-Lesioned or (-)-Pindolol-Pretreated Rats after Administration of Buspirone, Ipsapirone, or Gepirone
pp. 137-138(2)
Authors: Monti J.M.; Jantos H.; Silveira R.; Reyes-Parada M.; Scorza C.

Comparative Effects of Nefazodone and Fluoxetine on Sleep in Outpatients with Major Depressive Disorder
pp. 138-138(1)
Authors: Gillin J.C.; Rush A.J.; Armitage R.; Moldofsky H.

Specificity of Sleep EEG Changes in Psychiatric Disorders: Data from a Comparative Study
pp. 138-138(1)
Authors: Arriaga F.; Lara E.; Maltez J.; Cavaglia F.; Matos-Pires A.

Lipid Parameters in Depressed and Non-Depressed Patients with Sleep Apneas Syndrom
pp. 138-138(1)
Authors: Lemoine P.; Blassier A.; Hueber T.

Effects of Additional Bright Light Therapy on Sleep-EEG in Depressed Patients
pp. 138-139(2)
Authors: Hemmeter U.; Muller M.; Hatzinger M.; Seifritz E.; Bischof R.; Holsboer-Trachsler E.

The Effect of Paroxetine and Nefazodone on Sleep: A Placebo Controlled Trial
pp. 139-139(1)
Authors: Sharpley A.L.; Williamson D.J.; Attenburrow M.E.J.; Pearson G.; Sargent P.; Cowen P.J.

Atypical Neuroleptic Profile in Rodents of L-701,324, an Antagonist at the Glycine/NMDA Receptor
pp. 139-139(1)
Authors: Hutson P.H.; Tricklebank M.D.; Bristow L.J.

Clozapine in the Latent Inhibition (LI) Model: Atypical or a Typical Neuroleptic?
pp. 139-139(1)
Authors: Weiner I.; Shadach E.; Feldon J.

Specific Activation of Limbic Dopaminergic Structures in Rat Brain by Ca²⁺ Channel Blockers
pp. 139-139(1)
Authors: Vetulani J.; Antkiewicz-Michaluk L.

Dopamine Antagonists Increase Muscle Tone by Blocking Dopamine Receptors in the Substantia Nigra of the Rat
pp. 139-140(2)
Authors: Crocker A.D.; Hemsley K.M.

New Atypical Antipsychotics Olanzapine and ICI 204,636 vs Clozapine in 'D₁-Like' vs 'D₂-Like' Functional Models
pp. 140-140(1)
Authors: Deveney A.M.; Waddington J.L.

Glucocorticoid-Dependent AP-2 Activation of the Phenylethanolamine N-Methyltransferase Gene
pp. 140-140(1)
Authors: D. L.W.; Ebert S.N.

Antisense ''Knockout'' of Brain Dopamine Receptors
pp. 140-140(1)
Authors: Creese I.; Tepper J.; Sun B.; Ouagazzal A.; M. Z.

Behavioural and Biochemical Effects of Dopamine D3 Antisense Administration
pp. 140-141(2)
Authors: Ekman A.; Nissbrandt H.; Heilig M.; Eriksson E.

CAG Repeat Polymorphism in Schizophrenia
pp. 141-141(1)
Authors: H. G.H.; H. C.H.; C. T.C.; Y. L.L.

Acute Phase Proteins in Major Depression
pp. 141-141(1)
Authors: Berk M.; O'Neill-Kerr A.J.; Wadee A.A.

Plasma and Platelet Amino Acids in Major Depressed Patients Treated with Fluvoxamine
pp. 141-141(1)
Authors: Mauri M.C.; Ferrara A.; Boscati L.; Zamberlan F.; Alecci M.; Invernizzi G.

Refractory Depression a Biochemical Hypothesis
pp. 141-141(1)
Authors: Gupta R.K.; Norman T.R.; Burrows G.D.

Buspiron Augmentation of SSRI Therapy in Treatment-Refractory Depression
pp. 141-142(2)
Authors: Fahlen T.; &unknown;9gren H.; Edstrom A.; Rooth K.

Pramipexole in Major Depression -- An Open Clinical Trial
pp. 142-142(1)
Authors: Szegedi A.; Wetzel H.; Hillert A.; Benkert O.; Klieser E.; Gaebel W.

A Six Month Sertraline Fluoxetine Comparative Study in Depressed Outpatients: Outcome and Costs
pp. 142-142(1)
Authors: Bisserbe J.C.; Boyer P.; Souetre E.; Hotton J.M.; Troy S.

Comparison of Efficacy and Tolerability of Fluoxetine in Ambulatory and Hospitalized Patients with Major Depression
pp. 142-142(1)
Authors: Timotijevic I.; Paunovic V.R.; Pavlovic Z.

Comparison of Effects of Paroxetine and Amitriptyline on Driving and Psychomotor Performance in Depression
pp. 142-143(2)
Authors: SmithKline Beecham International; Starmer G.; Mascord D.

SSRI, L-Tryptophan and Serotonin Syndrome. Experience with 75 Patients
pp. 143-143(1)
Authors: Ciprian-Ollivier J.; Cetkovich-Bakmas M.; Albin J.; Vazquez G.

Antidepressants and Weight: A Comparative Study of Four Antidepressants and their Effect on Weight
pp. 143-143(1)
Authors: Joubert A.F.; Gagiano C.A.; Joubert G.

Similarities in Cognitive Impairment Profiles between Mild Dementia of Alzheimer Type and Anticholinergic Agent
pp. 143-143(1)
Authors: Morokawa Y.; Watanabe H.; Ohta T.; Yamaguchi N.; Aoba A.

Use of Anticholinergic Eye Drops in Differentiating Alzheimer's Disease and Depression
pp. 143-143(1)
Authors: Schweitzer I.; Chang V.; Kabov J.; Ames D.; Vingrys A.; Tuckwell V.

Scopolamine is a Model of Memory Dysfunction, not of Aging
pp. 144-144(1)
Authors: Riedel W.; Hogervorst E.; Verhey F.; Jolles J.

The M1 Muscarinic Agonist Xanomeline Improves Both Cognitive and Behavioral Deficits in Alzheimer's Disease
pp. 144-144(1)
Authors: Bodick N.; Offen W.

Pharmacological Studies on Bacopa Monniera, an Ayurvedic Nootropic Agent
pp. 144-144(1)
Authors: Dhawan B.N.; Singh H.K.

The Effects of Rilmenidine on Memory, Attention and Planning in the Elderly
pp. 144-144(1)
Authors: Mander A.G.; Conway E.L.; Louis W.J.

The Mechanism of Amyloid -Peptide (1-42) Toxicity in PC12 Cells
pp. 144-145(2)
Authors: Fagarasan M.; Efthimiopoulos S.

Prospective Study of the Effect of APOE Genotype on Cognitive Performance in the Very Old
pp. 145-145(1)
Authors: Altstiel L.; Mohs R.; Marin D.; Lebow L.; Yang X.-P.; Keddache M.; Greenberg D.

Cognitive Process Produces Inactivated Serotonin
pp. 145-145(1)
Author: Kishitani K.

Hypoxia and Hyperventilation as Models for Cognitive Deficiencies
pp. 145-145(1)
Authors: Hogervorst E.; Riedel W.; Van Boxtel M.; Visser P.; Hameleers P.; Sey S.; Jolles J.

Localization and Quantification of Serotonin-1a, MR and GR mRNA in Human Hippocampus
pp. 145-145(1)
Authors: Lopez J.F.; Little K.Y.; MacLaughlin D.P.; Watson S.J.

Long-Term Changes Induced by Anti-Depressant Drugs in the Presynaptic Release Machinery
pp. 145-146(2)
Authors: Popoli M.; Vocaturo C.; Buffa L.; Racagni G.; Perez J.

Modulation of 5-HT Activity by a New Endogenous Peptide, Directly Interacting at 5-HT_1B/1D Receptors
pp. 146-146(1)
Authors: Fillion G.; Rousselle J.C.; Massot O.; Fillion M.P.; Prudhomme N.; Hen R.

Effects of Psychoactive Agents on Second Messenger Formation in Rat Brain as Determined by in Vivo Microdialysis
pp. 146-146(1)
Authors: Newman M.E.; Gur E.; Lerer B.

Regulation of 5HT2A Receptors and Protein Kinase C by Dexamethasone and Corticosterone in the Rat Brain
pp. 146-146(1)
Authors: Dwivedi Y.; Dwivedi Y.; Pandey S.C.; Ren X.

Opioid Receptor Binding Properties of [³H]Buprenorphine in Rat Brain
pp. 146-147(2)
Authors: Borsodi A.; Otvos F.; Toth G.; Hosztafi S.; Simon C.; Benyhe S.

Phosphorylation by Ca²⁺/Calmodulin-Dependent Protein Kinase II. Effect on Ca²⁺/Phospholipid Binding
pp. 147-147(1)
Authors: Popoli M.; Buffa L.; Venegoni A.; Racagni G.

The Study of Signal Transduction During the Action of Some Memory Modulators
pp. 147-147(1)
Authors: Kulikova O.G.; Reikhardt B.A.; Sapronov N.S.

Protein Kinase C Regulates Platelet Serotonin Transporter
pp. 147-147(1)
Authors: Marazziti D.; Mazzoni M.R.; Palego L.; Sbrana A.; Fancelli M.; Rossi A.; Lucacchini A.

Co-Administration of Paroxetine and Haloperidol in Chronic Schizophrenia
pp. 147-147(1)
Authors: Lee M.S.; Kim S.H.; Han C.S.

SSRI Augmention of Antipsychotics in the Treatment of Negative Symptoms
pp. 147-147(1)
Author: Silver H.

Olanzapine X Haloperidol: The Results of a Double Blind Study on Acute Psychotic Patients
pp. 148-148(1)
Authors: Burgoyne K.; Ananth J.; Smith M.; Swartz J.R.; Gadasally R.; Arns P.

'Seroquel' (ICI 204,636): An Atypical Antipsychotic: Results from a Multiple Fixed Dose, Placebo-Controlled Study
pp. 148-148(1)
Authors: Arvanitis L.A.; Miller B.G.

Tolerability of Low Dose Neuroleptics: A Pseudoprospective, Blind Investigation of Flupenthixol
pp. 148-148(1)
Authors: Fritze J.; Spreda I.

Retrospective Study on Longtime Treatment with Clozapine
pp. 148-148(1)
Authors: Battegay R.; Das D.; Brogiolo G.; Wacker H.R.

Zotepine in Acute Exacerbation of Schizophrenia: A Comparison Versus Chlorpromazine and Placebo
pp. 148-148(1)
Authors: Cooper S.J.; Raniwalla J.; Welch C.

Controlled Comparison of Terguride and Perphenazine in Acute Schizophrenia
pp. 149-149(1)
Authors: Svestka J.; Ceskova E.; Kamenicka V.; Buresova A.

A Clinical Trial with Risperidon on Chronic Schizophrenics
pp. 149-149(1)
Authors: Bastaman T.K.; Budiman R.; Kumawardhani A.; Irmansyah A.N.; Salan R.

Clinical Trial on Antipsychotic Effects of the Sigma Ligand Panamesine in Schizophrenia
pp. 149-149(1)
Authors: Steiger A.; Frieboes R.-M.; Murck H.; Wiedemann K.

Dose Response of D-Cycloserine, a Partial NMDA-Glycine Site Agonist, in Schizophrenia
pp. 149-149(1)
Authors: D'Souza D.C.; Abi-Saab D.; Damon D.; White J.; Gil R.; Krystal J.H.

Treatment of Social Phobia
pp. 149-149(1)
Authors: Montgomery S.A.; Montgomery D.B.; Kotak A.

Social Phobia: A Debilitating Disease that Needs Treatment
pp. 150-150(1)
Authors: Lopez-Ibor J.J.; Gutierrez J.L.A.

Comorbidities in Social Phobia
pp. 150-150(1)
Author: Lecrubier Y.

Social Phobia: What is it and who has it?
pp. 150-150(1)
Author: Stein M.B.

Moclobemide for Anxiety Disorders: A Focus on Moclobemide in Panic Disorder
pp. 150-150(1)
Author: Tiller J.

Corticosteroid-Serotonin Interaction in Rat Brain: Pathophysiological Implications
pp. 150-151(2)
Authors: de Kloet E.R.; Meijer O.C.; Oitzl M.; Joels M.

Stress; Corticosteroids Hypersecretion; A Mono-Aminergic Dysregulation. A Depressogenic Cascade
pp. 151-151(1)
Author: Van Praag H.M.

Long-term Impact of Stressors and Affective Episodes on Vulnerability to Recurrence and Cycling
pp. 151-151(1)
Authors: Post R.M.; Weiss S.R.B.

Disturbed Hypothalamic-Pituitary Axis in Depression
pp. 151-151(1)
Authors: Nicholson C.; Peeters B.; Broekkamp C.

Antidepressants and the HPA System
pp. 151-151(1)
Author: Holsboer F.

Interactions between Cyclothiazide and 2,3-Benzodiazepines in Vivo and In Vitro
pp. 151-152(2)
Authors: Lodge D.; Bleakman D.; Palmer A.; Woolley M.; Bond A.

Allosteric Modulation of AMPA Receptor Function
pp. 152-152(1)
Authors: Partin K.; Fleck M.; Bowie D.; Bahring R.; Mayer M.L.

Thiazide Derivatives Block Rapid AMPA Receptor Desensitization
pp. 152-152(1)
Authors: Rothman S.M.; Yamada K.A.; Covey D.F.

Positive Allosteric Modulation of AMPA or GABA_A Receptors Antagonizes Alprazolam Induced Learning Impairment in Monkeys
pp. 152-152(1)
Authors: Costa E.; Auta J.; Thompson J.M.; Guidotti A.

Dopamine and Reward Mechanisms: Implications for Mood Disorders
pp. 152-152(1)
Author: Fibiger H.C.

Functions of the Central Dopamine Systems in Cognition; Relevance to Human Depression
pp. 153-153(1)
Author: Robbins T.W.